Author: Editor

ESMO 2025 breast cancer abstracts bring key updates. For example, Dr. Paolo Tarantino from Dana-Farber chose this top 10 list of ESMO 2025 breast cancer abstracts. It shows new treatments. Moreover, seven positive press releases point to changes in care. As a result, doctors can adjust their approaches based on these abstracts. Why These ESMO 2025 Breast Cancer Studies Matter This year, the conference highlights new drugs. For instance, antibody-drug conjugates lead the pack. They target cancer cells with precision. In addition, hormone treatments advance. Supportive care options grow too. Therefore, patients get better chances. #10: OptiTROP-Breast02 – New Option…

Introduction to a Revolutionary Cancer Approach This treatment starts with T cells from the patient. Doctors add receptors to spot cancer. Cells grow in a lab before returning to fight melanoma. It’s a promising option for tough cases, requiring an HLA match. Dr. Mehmi explains its impact. “We already have an approval in metastatic uveal melanoma patients with HLA O201, positive patients who haven’t seen prior therapies before,” says Inderjit Mehmi, MD. He adds, “And that trial, it was international trial, led to overall survival advantage in Uvial melanoma.” Understanding the Treatment Process The process involves collecting T cells. Then,…

Introduction to ESMO 2025 Genitourinary Cancer Abstracts ESMO 2025 genitourinary cancer abstracts show exciting new finds. For instance, they include a 78% rPFS boost in prostate studies. In addition, these works cover prostate, bladder, and kidney cancers. Experts ranked them by impact, trial stage, new ideas, and care changes. Moreover, the list comes from @OncoAlert. Now, let’s look at them. #10: DISCUS Trial Cuts Chemo Load The DISCUS trial checks 3 versus 6 chemo rounds before avelumab in urothelial cancer. For example, it signed up about 300 patients. In addition, it lowers chemo by 50%. Therefore, it reduces treatment strain.…

Immune checkpoint inhibitors myocarditis poses a serious threat in cancer care. These drugs fight tumors well. However, they can inflame the heart. For instance, about 1% of patients face this issue. But it can kill up to 50%. Therefore, oncologists need to stay vigilant. Key Risks of Immune Checkpoint Inhibitors Myocarditis First, understand how these inhibitors work. They block paths like PD-1 and CTLA-4. So, they boost the immune attack on cancer. Yet, this can harm the heart too. For example, combo therapies raise risks. Anti-CTLA-4 plus anti-PD-1 is one case. Also, thymoma patients have higher odds. Common Symptoms to…

TIL Therapy Breakthroughs for Oncologists and Oncology Professionals Tumor-Infiltrating Lymphocyte (TIL) therapy is transforming melanoma care and continues to provide new insights into TIL therapy melanoma management. Dr. Allison Betof Warner, Director of the Melanoma Program at Stanford University, leads this effort. Her work delivers stunning results for oncologists. Unmatched Survival and Response Rates Firstly, TIL therapy with lifileucel achieves a 96% 10-year survival rate for responders (Seitter et al. Clin Cancer Res 2021). This suggests a potential cure for metastatic cases. Additionally, for PD-1 refractory melanoma, the objective response rate (ORR) is 31.4%. Moreover, the disease control rate (DCR)…

Introduction to Neoadjuvant Therapy for Melanoma Neoadjuvant therapy is changing how we treat melanoma, offering big benefits over traditional adjuvant treatments alone. At the MOASC/ANCO Immuno-Oncology Symposium on September 6, 2025, Dr. Katy K. Tsai, MD, shared key insights. She serves as Associate Professor of Clinical Medicine and Medical Director of the Melanoma & Skin Cancer Program at the University of California, San Francisco. According to her, giving immunotherapy before surgery—while the tumor remains—helps the immune system recognize more tumor-specific antigens. This leads to a stronger, more varied response, which is a major advantage. Why Neoadjuvant Therapy Works The main…

The ESMO 2025 Congress, held October 17-21 in Berlin, will feature exciting breast cancer trials that could improve patient care. This countdown spotlights the top 10 trials, based on expert views and fresh data. Crafted for oncologists and healthcare workers, it includes antibody-drug conjugates (ADCs), CDK4/6 blockers, and survival results—giving practical tips for treatment. 10. 487MO: CDK4/6 Sequencing in HR+/HER2- Advanced Breast Cancer Noor Wortelboer’s study compares first- and second-line CDK4/6 blockers, showing better overall survival (OS) with first-line use. Additionally, adjust sequencing for ESR1-mutated patients. Moreover, this trial is key to the lineup. 9. 555MO: Dato-DXd + Durvalumab in…

On September 6, 2025, at the MOASC and ANCO Immuno-Oncology Symposium, Dr. Alexis LeVee, MD, from UCLA’s Division of Hematology/Oncology, shared exciting 2025 breast cancer immunotherapy trial updates. The session covered approved treatments, early-stage and metastatic strategies, new combinations, emerging drugs, and biomarkers. Therefore, these insights are vital for oncologists adapting to evolving care in triple-negative breast cancer (TNBC) and beyond. Approved Immunotherapy Treatments Breast cancer immunotherapy trial updates refine standards. Pembrolizumab is approved for early TNBC based on KEYNOTE-522. This trial showed better pathologic complete response (pCR) rates, event-free survival (EFS), and overall survival (OS) with added immunotherapy. In…

FDA Backs Lurbinectedin + Atezolizumab for ES-SCLC Care FDA approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals) with atezolizumab (Tecentriq, Genentech) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) to maintain treatment in adults with extensive-stage small cell lung cancer (ES-SCLC). This applies to patients stable after initial care with atezolizumab (or Tecentriq Hybreza), carboplatin, and etoposide. For oncology experts, the IMforte trial (NCT05091567) provides solid data on survival and safety. Full details are on Drugs@FDA. Let’s look at the key numbers to guide your work. IMforte Study Design The IMforte study, a randomized phase III trial, tested this treatment after initial care. Here’s the…

Introduction to ASCO 2025 Lung Cancer Immunotherapy Updates At the MOASC/ANCO Immuno-Oncology Symposium held on September 6, 2025, in Marina del Rey, Dr. Navid Hafez, MD, MPH, delivered a compelling overview of ASCO 2025’s most impactful lung cancer immunotherapy data. Drawing from the symposium’s focus on advancing cancer care in California, Dr. Hafez highlighted transformative results in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). These updates, rooted in Phase III trials, emphasize improved pathologic complete response (pCR) rates and overall survival (OS) benefits. Even the role of infusion timing was emphasized. For Northern California’s oncology community,…

Introduction: A New Tool for Breast Cancer Treatment On September 25, 2025, the FDA approved Inluriyo (imlunestrant), an oral selective estrogen receptor degrader (SERD), for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer (MBC) after progression on endocrine therapy (ET). 0 For oncologists, this Inluriyo FDA approval offers a targeted oral therapy to tackle ET resistance. Consequently, this post provides key trial results, safety data, dosing details, and practical steps for oncology practice. Who Qualifies for Inluriyo? Inluriyo is approved for adults with ER+, HER2-, ESR1-mutated advanced or MBC after prior ET, such as aromatase inhibitors with or without CDK4/6…

Uncommon EGFR Mutations Research Overview At MOASC Spotlight 2025, Dr. Darren Wijaya, MD, from Loma Linda University Health, shared vital research. It focused on rare and uncommon EGFR mutations in metastatic lung cancer. Uncommon EGFR mutations in lung cancer present unique challenges in treatment. The study involved 10 patients. Dr. Wijaya is a third-year internal medicine resident. Learn more about his work here. Key Results for Rare EGFR Changes The study showed a Median Progression-Free Survival (PFS) of 15.81 months. Furthermore, the Median Duration of Response (DoR) was 22.1 months. Additionally, the Objective Response Rate (ORR) hit 40% at 6…

In 2025, the US Surgeon General issued a pivotal advisory on alcohol and cancer risk, urging updated warning labels, patient counseling, and clinical interventions. Consequently, this post summarizes a comprehensive JAMA review led by Kenneth L. Morford, MD, of Yale School of Medicine, outlining the science and prevention strategies. For a visual overview, watch our OncologyTube video: Alcohol-Related Cancers: A Global Concern Alcohol is a known carcinogen, directly linked to cancers of the mouth, pharynx, larynx, esophagus, breast, colorectum, and liver. For example, a 2020 global study found alcohol caused 740,000 cancer cases—4.1% of all cancers, with 76.7% in men.…

Oncology changes quickly. The melanoma treatment updates 2025 from the ASCO Annual Meeting offer vital help. Dr. Gino K. In, MD, MPH, from USC Norris Comprehensive Cancer Center, shared insights. His talk happened at the MOASC Spotlight 2025 in Newport Beach, CA. It covered therapy sequencing for BRAF V600-mutant melanoma. He also discussed Lifileucel and adjuvant PD-1 for high-risk CSCC. These updates show strong, immunotherapy-led plans. They boost survival and life quality. The findings come from trials like DREAMSeq, C-144-01, and C-POST. Dr. In’s presentation can change practice. It aids healthcare workers and patients. Therefore, these updates bring hope and…

Paraneoplastic syndromes can signal hidden cancers. Dr. Nirja Shah, MD, from UC San Diego Health, shared a rare case study. She presented at the MOASC Spotlight 2025 in Newport Beach, CA. Her interview showed how anti-Yo antibodies uncovered bilateral breast cancer. This case links neurology and oncology. Now, let’s dive into the details. Patient Presentation: First Symptoms A 44-year-old nurse visited the emergency room. She had dizziness, unsteadiness, and clumsy hands for 10 days. Dr. Shah said, “She came into the emergency department with a 10-day history of ataxia, clumsiness, and dizziness.” She had no fever or nausea. Her past…

At the MOASC Spotlight 2025 in Newport, California, Dr. Victoria M. Villaflor, MD, shared exciting head and neck cancer ASCO 2025 updates. As Director of UCI Health’s Head and Neck Oncology Program, she focuses on team-based care and new therapies. Moreover, her interview highlights key trials like C-POST, NIVOPOSTOP, and advances in nasopharyngeal cancer (NPC). These head and neck cancer ASCO 2025 findings offer hope for better outcomes. Let’s explore the top insights. Cemiplimab: A New Standard for Skin Cancer Cutaneous squamous cell carcinoma (SCC) often returns—up to 30% of cases within five years after surgery and radiation. However, the…

The ASCO 2025 breast cancer updates revealed exciting changes in treatment for triple-negative breast cancer (TNBC) and HER2-low cases. For example, Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor and Breast Medical Oncologist at UC Irvine, shared key results from the ASCENT-04 and COMPASSHER2 trials during a spotlight session. Consequently, her talk showed how these findings could improve patient care with targeted, less invasive therapies. Whether you’re a doctor, patient advocate, or researcher, these breast cancer updates offer hope. Let’s explore Dr. Lavasani’s insights. Better Neoadjuvant Therapy: COMPASSHER2 and HER2-Low Findings First, the EA1181/CompassHER2 pCR trial stood out…

At the 2025 MOASC Spotlight in Newport Beach, CA, Dr. Miguel Villalona-Calero, MD, from the University of California Irvine, shared key ASCO 2025 lung cancer advances. His OncologyTube interview and slide deck highlight progress in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). For example, trials like NeoADAURA, DeLLphi-304, and KRYSTAL-7 show promise for targeted therapies and immunotherapy. These insights could transform oncology practice. These Lung Cancer ASCO 2025 Updates indicate significant strides in the field. Watch the interview and download the slide deck for trial details from the Lung Cancer ASCO 2025 Updates. [Embed Video: Dr.…

At the MOASC Spotlight 2025, Dr. Joshua G. Cohen, M.D., F.A.C.O.G., F.A.C.S., Medical Director of the Gynecologic Cancer Program at City of Hope Orange County, shared transformative updates on ovarian cancer treatment advancements. His presentation highlighted novel therapies, surgical strategies, and molecular testing that are reshaping care for patients with ovarian cancer. Below, we summarize key insights for medical professionals and patients, featuring critical findings from recent trials. Breakthroughs in Low-Grade Serous Ovarian Cancer Low-grade serous ovarian cancer is notoriously resistant to traditional chemotherapies. Dr. Cohen emphasized, “The new combination of abibittnib and deactnib represents really a first in class novel combination to…

The FDA approved INLEXZO™ / gemcitabine intravesical on September 9, 2025, to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). This innovative therapy, known as INLEXZO gemcitabine intravesical, offers oncologists and patients a new way to manage this tough condition. For example, it helps those seeking to avoid surgery. What is INLEXZO™ / Gemcitabine Intravesical? INLEXZO™ / gemcitabine intravesical delivers 225 mg of gemcitabine to the bladder. A doctor inserts it using a catheter and stylet in a quick outpatient visit, needing no anesthesia. The treatment plan includes ensuring that INLEXZO gemcitabine intravesical is easily administered…

ASCO 2025 and the MOASC Conference unveiled major progress in colon cancer treatment advancements. For example, the CHALLENGE study showed exercise greatly improves survival. Additionally, new therapies like immunotherapy, targeted drugs, aspirin, and ctDNA testing offer hope for stage 3 and advanced cases. This article explores these colon cancer treatment advancements, shared at the Missouri Oncology Society Conference, and their benefits for patients. Why ASCO and MOASC 2025 Are Key for Cancer Care The ASCO Annual Meeting is a global hub for cancer research. It shares new trial results. Meanwhile, the MOASC Conference brings these findings to local doctors. Together,…

Genitourinary oncology is advancing fast. At the MOASC Spotlight on Oncology event on August 16, 2025, at VEA Newport Beach, we interviewed Dr. Nataliya Mar, MD, Assistant Professor — Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine. As a top US genitourinary oncologist, Dr. Mar specializes in prostate, bladder, renal, and testicular cancers. She shared key ASCO 2025 genitourinary cancer updates. This post highlights her insights for oncology professionals seeking the latest research. NIAGARA Study: ctDNA in Bladder Cancer The NIAGARA trial added durvalumab to chemotherapy for muscle-invasive bladder cancer (MIBC). It showed ctDNA as a vital…

This report examines the NSCLC HER3-DXd breakthrough. It focuses on its potential impact on patients with resistant EGFR-mutated non-small cell lung cancer (NSCLC). The HERTHENA-Lung02 phase 3 study, based on data as of 08:44 AM PDT, August 18, 2025, provides details on patritumab deruxtecan (HER3-DXd) following third-generation EGFR TKI failure. The analysis includes key statistics, such as a 23% reduction in progression risk and improved PFS rates. Additional resources are available on OncologyTube.com, with related content at Top Advances in Lung Cancer 2025. The Unmet Challenge in NSCLC NSCLC continues to pose a significant health challenge, particularly when EGFR-mutated, as…

OncologyTube brings you an exclusive look at the AMPLIFY-201 Phase 1 trial. Furthermore, this study highlights ELI-002 2P, a lymph node-targeted mKRAS vaccine for pancreatic cancer and colorectal cancer patients with minimal residual disease (MRD+). Published in Nature Medicine (full study), this trial offers fresh insights into cancer care. The Challenge of Pancreatic Tumors Pancreatic cancer, where KRAS mutations affect 93% of cases, poses a tough problem. Additionally, MRD+ patients face a 23% 5-year survival rate after relapse. However, ELI-002 2P’s amphiphile method boosts lymph node delivery, improving treatment options. Trial Design and Patient Selection The study involved 25 patients,…

At the ASBrS 2025 annual meeting, Dr. Lucy Maria De La Cruz, MD, from Georgetown University Hospital, shared vital insights on male breast cancer treatment. Her talk, “The Forgotten Breast,” covered hormonal differences, effective therapies, and new research like the ETHAN study. Male Breast Cancer: A Unique Challenge Male breast cancer (MaBC) is rare but needs specific care. Dr. De La Cruz said, “Mil cancer patients have 80% of their estrogen incomes from peripheral conversion, and 20% comes from their gesticular excretion. It’s very different than women.” Unlike women, who rely on ovarian estrogen before menopause, men depend on peripheral…

I’m sharing an actual recent peer-to-peer call that shows what physicians and patients face when trying to get a surgery approved. This call felt as absurd as it sounds.The peer-to-peer call was to advocate for surgery to prevent and treat lymphedema for a patient with breast… pic.twitter.com/SJz6ToWN8u— Elisabeth Potter MD (@EPotterMD) July 11, 2025 The Frustration of Peer-to-Peer Calls Dr. Elisabeth Potter, MD (@EPotterMD), recently shared a frustrating experience on X about a peer-to-peer (P2P) prior authorization call. This was for lymphovenous bypass (LVB) surgery, revealing the breast cancer treatment challenges faced by patients. This procedure aims to prevent lymphedema…

What Are CDK4/6 Inhibitors? CDK4/6 inhibitors, such as abemaciclib and ribociclib, are changing breast cancer treatment for HR+/HER2- early-stage patients. Specifically, these drugs target a key cell growth pathway to tackle hormone therapy resistance, a major issue in high-risk cases. For example, Dr. Austin Williams, a breast surgeon at Fox Chase Cancer Center, explains in a recent interview that these drugs work inside cells to boost treatment success. How Do These Drugs Work? In simple terms, CDK4/6 inhibitors stop a protein complex that drives cell growth, halting tumor cells in their tracks. As a result, they prevent cancer from spreading,…

Sensation-preserving mastectomies are transforming breast cancer surgery. They prioritize oncologic safety and sensory recovery. In an exclusive interview, Dr. Anne Peled, a leading breast and plastic surgeon, shares her expertise. Below, we explore their safety, and their benefits. What Are Sensation-Preserving Mastectomies? Sensation-preserving mastectomies aim to maintain or restore breast sensation after surgery. Dr. Peled explains, “The goal is two-pronged: preserve nerves in the fat layer and reconstruct those in the breast tissue.” For example, nerves in the fat layer are kept when safe. However, nerves in the breast tissue are cut for a thorough mastectomy and then reconstructed. This…

A major study, NRG-NSABP B-51/RTOG 1304, published on June 4, 2025, in the New England Journal of Medicine, shows regional nodal irradiation (RNI) does not lower breast cancer recurrence. This applies to patients whose lymph nodes turn negative after chemotherapy. The study is changing breast cancer treatment, offering simpler, effective care. Key Findings of the Breast Cancer Treatment Study The study included 1,641 patients with node-positive breast cancer that became node-negative after chemo. Patients had either lumpectomy or mastectomy. Lumpectomy patients got radiation to the breast alone or with lymph nodes. Mastectomy patients received chest wall and lymph node radiation…

The I-SPY2 Trial is transforming breast cancer treatment, offering new insights into pre-surgery chemotherapy for invasive lobular breast cancer (ILC). Presented at the 2025 American Society of Breast Surgeons (ASBrS) meeting, this study explores surgical outcomes and lymph node response in high-risk tumors. In an exclusive interview, Rita Mukhtar, MD, a breast surgeon at UCSF, shares how the MammaPrint assay enhances breast cancer care by identifying ILC patients who benefit from chemotherapy. Therefore, this 2025 breakthrough is shaping personalized treatment for breast cancer. Understanding the I-SPY2 Trial The I-SPY2 Trial (2010–2021) tests pre-surgery chemotherapy to improve breast cancer treatment in…

The 2025 Cell article by Catherine M. Phelps et al. from the University of Pittsburgh reveals a key connection between exercise, the gut microbiome, and melanoma immunotherapy. This web companion, linked to an upcoming OncologyTube Exclusive video set to launch soon, explores this groundbreaking research published on July 9, 2025. Perfect for cancer researchers, this guide examines the science, practical uses, and unanswered questions, updated as of 07:13 AM PDT, July 11, 2025. How Exercise Enhances Melanoma Immunotherapy Exercise acts as a strong aid in cancer care, reshaping the gut microbiome to boost melanoma immunotherapy. The 2025 Cell article shows…

The U.S. healthcare sector is transforming rapidly, solidifying its position as the nation’s top expenditure and a powerhouse for job growth. For oncologists and cancer researchers, this shift offers critical opportunities and challenges. In 2023, healthcare spending reached $4.9 trillion, or 17.6% of GDP, outpacing housing and food [1]. This post dives into the surge in oncology jobs, escalating cancer care costs, and their implications for 2025, tailored for the OncologyTube.com community. The Surge in Oncology Jobs Healthcare is redefining the U.S. economy, adding over 500,000 jobs in 2025, with oncology roles like medical oncologists and researchers leading the charge…

Breast surgery is transforming patient care with innovative approaches. Oncoplastic breast surgery, for instance, merges art and science to improve outcomes. Dr. Barry Rosen, a breast surgeon at Advocate Health, shares insights from a survey of 36 oncologists. Evolving Treatment Choices Breast surgery has reshaped options for patients. Oncoplastic breast surgery moves beyond the traditional lumpectomy or mastectomy dilemma. Dr. Barry Rosen explains, “Breast surgery has really changed how we plan ideal outcomes.” This evolution offers tailored procedures, from basic lumpectomies to advanced mastectomies. Oncoplastic techniques surely add more options. Learn more at American Cancer Society. Watch Dr. Rosen in…

At ASBrS 2025, experts showcased how MRD testing in breast cancer is revolutionizing patient care. Using Natera’s Signatera, clinicians detect circulating tumor DNA (ctDNA) to identify recurrence risks early. This post dives into the key takeaways, exploring MRD testing’s role in neoadjuvant, adjuvant, and surveillance settings. What Is MRD Testing in Breast Cancer? MRD testing identifies cancer DNA in the blood post-treatment. Unlike imaging, which may miss early signs, Signatera’s tumor-informed approach offers unmatched sensitivity. By sequencing tumor-specific mutations, it pinpoints patients needing escalated therapy or those who can avoid overtreatment. Up to 30% of breast cancer patients face recurrence. MRD testing enables early…

The Camizestrant SERENA-6 trial shone at ASCO 2025, presented by Professor Nick Turner. This Phase 3 study targets ESR1-mutated, ER-positive, HER2-negative breast cancer. It shows better progression-free survival (PFS) for patients, as reported in the New England Journal of Medicine. Let’s explore the trial’s key findings. What is the Camizestrant SERENA-6 Trial? The SERENA-6 trial, funded by AstraZeneca, tests camizestrant’s effectiveness. It focuses on ESR1 mutations, which resist standard breast cancer treatments. Camizestrant, a next-generation SERD, blocks estrogen receptors completely. Thus, it offers a new way to fight resistant tumors. Trial Design The trial screened 3,256 patients for ESR1 mutations…

Introduction to CT Scans and Cancer Computed Tomography (CT) scans are vital for diagnosing cancer, injuries, and chronic diseases. However, a 2025 study in JAMA Internal Medicine highlights significant CT scans and cancer risks, projecting 103,000 future cancers from 93 million scans performed in 2023 [1]. This post explores the study’s findings, high-risk groups, and actionable steps to minimize risks, led by Dr. Rebecca Smith-Bindman at the University of California, San Francisco [2]. Key Findings from the 2025 Study The study, published in JAMA Internal Medicine [1], used data from the UCSF International CT Dose Registry (2018–2020) to estimate lifetime…

Introduction to Datopotamab Deruxtecan EGFR-Mutated NSCLC On June 23, 2025, the FDA approved Datopotamab Deruxtecan EGFR-Mutated NSCLC treatment, known as datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), for adults with advanced cases after prior therapies. This approval provides a new option for patients and a research focus for scientists. This article details the Datopotamab Deruxtecan EGFR-Mutated NSCLC process for both groups. Watch our video [insert video link here] for a summary. Understanding EGFR-Mutated NSCLC Treatment For Patients: EGFR-mutated NSCLC is a type of lung cancer caused by gene changes. If you have tried EGFR inhibitors or chemotherapy, datopotamab deruxtecan may be…

Introduction to Post-CDK4/6 Inhibitor Treatment Treating hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC) has improved with CDK4/6 inhibitors like palbociclib. However, progression after this therapy creates challenges for clinicians. This guide to post-CDK4/6 inhibitor treatment explores the latest strategies, based on Teysir et al. (2025) in the ASCO Educational Book [link: https://ascopubs.org/doi/pdf/10.1200/EDBK-25-473372]. Moreover, we cover resistance, new therapies, and global access to help oncologists and researchers. Understanding Resistance Mechanisms Genomic Drivers of Resistance Resistance often stems from genomic changes. ESR1 mutations in 20-50% of cases, causing endocrine resistance. Furthermore, PI3K/AKT pathway shifts affect over 50% of tumors, per a…

FDA Voucher Program Oncology: Accelerated Approvals in Oncology On June 17, 2025, the FDA launched the Commissioner’s National Priority Voucher (CNPV) program. This initiative aims to speed up drug approvals for treatments aligned with U.S. health priorities, including oncology. Understanding its impact on oncology drug approvals is crucial. Therefore, this post explores how the new FDA voucher program affects the oncology field, focusing on key areas such as accelerated timelines and safety standards. Accelerated Timelines for Oncology Drug Approvals The program reduces review times from 10-12 months to 1-2 months. In oncology, this could mean quicker access to new therapies…

Welcome to this comprehensive web companion for the OncologyTube.com video, “HR+/HER2- metastatic breast cancer 2L outcomes: Top 10 from ASCO 2025.” This article elaborates on HR+/HER2- metastatic breast cancer 2L outcomes, as presented by Komal Jhaveri, MD, FACP, at ASCO 2025. It explores second-line (2L) and beyond treatment results for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Whether you’re an oncologist, researcher, or patient advocate, this resource provides critical clinical data, focusing on median progression-free survival (mPFS). To deepen your understanding, watch the OncologyTube.com video (#) and download the slide deck. For more breast…

Welcome to this exclusive OncologyTube.com companion to our video, “Comprehensive Overview of Bispecific Antibodies in Cancer Therapy.” Bispecific antibodies (bsAbs) are transforming cancer immunotherapy 2025 by targeting two antigens to boost tumor destruction. This post, inspired by Klein et al. (2024) in Nature Reviews Drug Discovery, offers deep insights into clinical data, trials, and future trends in bsAb oncology. Whether you’re an oncologist or researcher, this guide provides valuable takeaways. What Are Bispecific Antibodies? Firstly, bispecific antibodies are innovative molecules that bind two targets, such as CD3 on T cells and CD19 on cancer cells. This dual action redirects the…

China is making significant strides in oncology research. Data from the IQVIA Global Oncology Trends 2025 report highlights China’s growing role in clinical trials and novel cancer drugs. Therefore, this video companion explores these developments in detail. In addition, watch our exclusive video on OncologyTube.com for more insights! Why China Matters in Oncology China’s oncology trials have increased from 5% in 2009 to 39% in 2024. This growth exceeds other nations. Moreover, the country’s focus on advanced therapies supports this trend. As a result, let’s examine the data closely. Key Highlights from the IQVIA Report Surge in Clinical Trials China…

Introduction to HCC Treatment Insights Hepatocellular carcinoma (HCC) presents tough treatment challenges, requiring careful patient selection for local therapies. This guide for HCC treatment selection and its companion video on OncologyTube.com originate from an infographic presented at ASCO 2025 (see related links). Therefore, we explore the latest HCC treatment selection recommendations using data from ASCO 2025, AASLD guidelines, and the 2024 JCO RCT. This resource helps oncologists and researchers stay informed. Understanding Key Criteria Effective HCC management depends on matching therapies to patient and tumor traits. Let’s break it down further: Tumor Size: Tumors Under 3 cm For small, non-invasive,…

On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a new kinase inhibitor. FDA approval of taletrectinib for ROS1-positive NSCLC is a significant advancement. This treatment is for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Meanwhile, this is big news for patients with this rare lung cancer type. How Was Taletrectinib Tested? The FDA evaluated taletrectinib using data from two clinical trials: TRUST-I (NCT04395677) and TRUST-II (NCT04919811). These were multicenter, single-arm, open-label studies. In addition, FDA’s approval of taletrectinib for ROS1-positive NSCLC included 157 treatment-naive patients (103…

The ASCO 2025 conference, held recently, shared new research that may shape cancer treatments. This article covers studies on treatment-induced lymphopenia, lymphocyte stability in immunotherapy, and early work on the Cancer Bioshield platform. Dr. Pat Soon-Shiong reported these findings on June 7, 2025, via X. They offer key data for oncologists and researchers. A companion video on OncologyTube.com adds visual details. Treatment-Induced Lymphopenia in Lung Cancer A study from Ohio State University, titled “Survival Impact of Lymphocytopenia during Chemoradiation in Locally Advanced NSCLC Patients Treated with Adjuvant Durvalumab,” focused on 118 Stage III lung cancer patients. They received chemoradiation and…

Digestive cancers therapeutics takes center stage as these cancers—esophageal, gastric, biliary, pancreatic, hepatocellular, and colorectal—account for 33-35% of global cancer deaths. A recent review in Nature’s Signal Transduction and Targeted Therapy by Zhan et al. (2025) offers fresh insights into their causes, treatments, and future directions. This post explores key findings, including clinical trials and innovative cancer treatments shaping oncology care. Watch our exclusive video on OncologyTube.com for a quick overview! The Global Impact of Cancer Treatments First, let’s examine the scale of Digestive Cancers Therapeutics. For example, colorectal cancer is the most common digestive cancer globally, except in Africa.…

On June 3, 2025, the U.S. Food and Drug Administration (FDA) approved Darolutamide for de novo metastatic castration-sensitive prostate cancer (mCSPC), marking a notable advancement in prostate cancer care. This post delves into the data behind this Darolutamide FDA Approval 2025, its implications, and its significance for oncologists and researchers. A 10-Year Evolution of FDA-Approved mCSPC Therapies The progression of mCSPC treatment reflects a decade of FDA approvals, detailed in recent analyses. Key milestones include: This evolution highlights Darolutamide’s expanded role without chemotherapy. Learn more about the FDA approval process for such therapies. Efficacy Comparison Across Treatments Efficacy varies across…

Tarlatamab Phase 3 Results SCLC ASCO 2025 The tarlatamab phase 3 results for SCLC, shared at ASCO 2025, showed a notable improvement in survival. Tarlatamab achieved a median overall survival (mOS) of 13.6 months compared to 8.3 months with chemotherapy. The hazard ratio (HR) was 0.6, with a p-value less than 0.001, indicating statistical significance. At 12 months from randomization, 62% of tarlatamab patients were alive, compared to 37% in the chemotherapy group. Overview of the DeLLphi-304 Study Design The DeLLphi-304 study is a randomized, controlled phase 3 trial that enrolled 509 patients with relapsed SCLC. Patients were required to…

Introduction to Pancreatic Cancer Treatment at ASCO 2025 At the ASCO 2025 Annual Meeting, Dr. Brian Wolpin presented groundbreaking updates on pancreatic cancer treatment, specifically for pancreatic ductal adenocarcinoma (PDAC). For instance, these insights, shared by Dr. Amol Akhade on X, provide a clear roadmap for oncologists managing different stages of PDAC. In this post, we’ll break down the key findings from ASCO 2025. Additionally, we’ll share a concise video summarizing the current standards of care. Watch the video on OncologyTube.com to stay ahead in pancreatic cancer treatment strategies. Watch the Video on Pancreatic Cancer Treatment Standards The video highlights…

At the 2025 ASCO Annual Meeting, new data on IO-based combinations in mRCC emerged. For instance, Dr. Brian Rini, MD shared results from four trials. These were CheckMate 214, KEYNOTE-426, CheckMate 9ER, and CLEAR. Moreover, they compared immunotherapy regimens in kidney cancer. As a result, the findings help oncologists and cancer researchers. In fact, they improve survival and disease control in mRCC. Key ASCO25 Data on IO-Based Combinations in mRCC The trials showed major progress in mRCC treatment. Specifically, IO-based combinations in mRCC outperformed single-agent TKIs. Therefore, here are the key points for oncologists: Challenges in mRCC Trial Comparisons Cross-trial…

This video presents the myeloma treatment algorithm 2025 for transplant-ineligible patients, shared by Dr. Vincent Rajkumar at ASCO 2025. Designed for oncology professionals on ASCO.org and OncologyTube.com, it explains treatment strategies for varied patient needs. What the Video Covers Why This Algorithm Is Relevant A 2024 NCI trial showed Dara-VRd reduced progression risk by 60% compared to VRd alone, with 84% of Dara-VRd patients progression-free after 4 years versus 68% for VRd. This algorithm incorporates such data to guide oncologists. It also considers practical issues, like treatment access, making it applicable in diverse clinical settings. For hematologists, researchers, and clinicians,…

At the 2025 ASCO Annual Meeting, a phase 3 randomized trial revealed that the timing of immunotherapy in non-small cell lung cancer (NSCLC) significantly affects patient outcomes. This study, presented by Dr. Yongchang Zhang from Hunan Cancer Hospital, showed that infusions administered before 3 PM led to better progression-free survival (PFS) and overall survival (OS) compared to later infusions. Let’s dive into the findings and their implications for clinical practice. Study Design: Randomized Trial on Timing of Immunotherapy in NSCLC The study involved 210 patients with stage IV NSCLC, randomized into two groups of 105 each. One group received immunotherapy…

What’s New at ASCO 2025? The ASCO 2025 conference in Chicago brought exciting news for cancer care. A major study, the CHALLENGE Trial, was published in the New England Journal of Medicine on June 1, 2025. It shows how structured exercise helps colon cancer survivors live longer after chemotherapy. What Is the CHALLENGE Trial? The CHALLENGE Trial studied 889 colon cancer patients. It compared two groups over 7.9 years: one did a 3-year exercise program, while the other got health education. The goal was to see how exercise affects survival. How Does Exercise Help Survival? The trial focused on Disease-Free…

ATOMIC Trial ASCO 2025: Key Results RevealedOn June 1, 2025, the ASCO Annual Meeting in Chicago presented the ATOMIC trial ASCO 2025 results. This phase III study focuses on stage III dMMR colon cancer treatment. Researchers tested atezolizumab with mFOLFOX6 against mFOLFOX6 alone. The trial showed a clear improvement in disease-free survival for patients. This post explains the findings for oncology professionals. Details of the ATOMIC TrialThe ATOMIC trial included 712 patients with dMMR stage III colon cancer. From 2017 to 2023, researchers divided them into two groups. One group of 355 patients received atezolizumab and mFOLFOX6. The other group…

Introduction Cancer of Unknown Primary (CUP) diagnostics is a critical area for oncologists and researchers, as 2-5% of cancer cases lack an identifiable origin. An OncologyTube video, based on a May 2025 review by Kanwal Raghav, M.D., in the New England Journal of Medicine (NEJM), examines the latest approaches to diagnosing and treating CUP. This post summarizes the video’s insights on Cancer of Unknown Primary diagnostics, including immunophenotyping, molecular profiling, and ASCO guidelines. These strategies aim to improve outcomes for CUP patients. Defining Cancer of Unknown Primary (CUP) CUP refers to cancers where the primary site of origin remains unidentified…

Published: May 30, 2025 Pfizer shared results from the BRAFTOVI BREAKWATER trial at ASCO 2025. The trial tested BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). This post details the findings, based on a Pfizer press release. A video summary is also available. What Is the BRAFTOVI BREAKWATER Trial? The BRAFTOVI BREAKWATER trial is a Phase 3 study. It compared BRAFTOVI with cetuximab and mFOLFOX6 to standard chemotherapy in 479 patients with BRAF V600E-mutant mCRC. Specifically, 236 patients received the BRAFTOVI regimen, while 243 got standard treatments like mFOLFOX6 or CAPOX, with or without bevacizumab. The trial measured…

Posted on May 30, 2025 by ASCO Editorial Team Artificial intelligence (AI) is reshaping the future of cancer research and care. At the ASCO 2025 Annual Meeting, three education sessions will dive into how AI is revolutionizing oncology, from clinical trials to patient care. This post explores these sessions, their key takeaways, and what they mean for the future of cancer treatment. The Rise of AI in Cancer Research AI in oncology is making waves by streamlining processes and enhancing patient outcomes. From planning clinical trials to supporting therapeutic decisions, AI is becoming a game-changer in cancer care. The ASCO…

The Top 10 GI Trials at ASCO 2025 are here (with Dates and Times), and OncologyTube proudly presents an exclusive video to explore the latest breakthroughs in gastrointestinal oncology. This video highlights the most impactful trials at ASCO 2025, in Chicago from May 30 to June 3, 2025. Whether you’re a medical professional or a patient seeking advanced treatments, these trials provide valuable insights into the future of GI cancer care. Moreover, from the ATOMIC Trial to the POLCAGB Trial, the video covers innovative therapies that could transform lives. Therefore, watch the video above to learn more, and continue reading…

Former President Joe Biden’s Stage 4 prostate cancer diagnosis, announced on May 27, 2025, raises profound questions. When did this silent, aggressive cancer take root? Could it have been present during his presidency (2021–2025), undetected despite top-tier medical care? The Joe Biden prostate cancer timeline challenges assumptions about cancer’s stealth. Our OncologyTube video explores this mystery, and this post summarizes key insights from leading experts. How does a high-profile case like Biden’s reshape our understanding of prostate cancer’s hidden progression? Biden’s Diagnosis: A Medical Enigma In May 2025, at age 82, Biden faced a shocking diagnosis: Stage 4 prostate cancer.…

OncologyTube.com presents the ASCO 2025 Top 10 Abstracts, highlighting practice-changing trials in oncology. It features advancements in cancer care, from colon cancer to Polycythemia Vera. Trials like ATOMIC and VERIFY are among the highlights. Therefore, let’s explore the ASCO 2025 Top 10 Abstracts, presented in reverse order for a unique perspective. Top 10 ASCO 2025 Abstracts: Numbers 10 to 8 This list counts down the ASCO 2025 Top 10 Abstracts, showcasing impactful oncology trials in a reversed sequence. Firstly, we begin with the studies ranked 10 to 8. #10: VERIFY Phase III: Polycythemia Vera Therapy #9: NIVOPOSTOP Phase III: Head…

Publish Date: May 23, 2025Category: Cancer Research Funding Introduction to the 2026 Cancer Research Budget The proposed 2026 cancer research budget introduces significant changes to funding for cancer research in the United States. Specifically, the National Cancer Institute (NCI), the primary federal agency for cancer research, faces a potential reduction in its budget. This post examines the differences between the 2025 and 2026 NCI budgets, focusing on the numbers and the broader context of NIH funding. Watch our companion video on OncologyTube.com for a detailed breakdown of these changes. NCI Budget in 2025: A Baseline In 2025, the NCI’s budget…

The American Society of Clinical Oncology (ASCO) Annual Meeting is a pivotal event for oncology professionals, and ASCO 2025, happening from May 31 to June 2, is no exception. In this OncologyTube exclusive video, we’re counting down the Top 10 breast cancer trials you won’t want to miss. From groundbreaking therapies to long-term updates, these presentations will shape the future of breast cancer treatment. Let’s dive in! 10. NeoSTAR Trial Presentation: June 1, 8:12 AMThe NeoSTAR trial evaluates neoadjuvant sacituzumab govitecan (Trodelvy) combined with pembrolizumab (Keytruda) in early triple-negative breast cancer (TNBC). This study could redefine early-stage TNBC treatment strategies.…

RAS Inhibitor Resistance in PDAC at AACR 2025 At the AACR 2025 Annual Meeting in Chicago, Dr. Andrew Aguirre from the Dana-Farber Cancer Institute presented findings on RAS inhibitor resistance in PDAC (pancreatic ductal adenocarcinoma). This cancer type has a 5-year survival rate of 10% and is often driven by KRAS mutations, which are found in 95% of cases. Understanding resistance to RAS inhibitors is important for improving treatment outcomes in PDAC. This post summarizes the OncologyTube video covering Dr. Aguirre’s session, focusing on resistance mechanisms, challenges, and future research directions. The Role of RAS in PDAC RAS proteins, especially…

A New Approach to MMRd/MSI-H Tumors At the AACR Annual Meeting 2025 in Chicago, Dr. Andrea Cercek presented compelling data on PD-1 immunotherapy for MMRd/MSI-H tumors. Her phase II trial of 117 patients showed a 92% recurrence-free survival (RFS) rate at two years, with 35% experiencing no adverse events. This study, focusing on cancers like colorectal and endometrial, suggests PD-1 immunotherapy could redefine treatment for MMRd/MSI-H tumors. Watch our detailed video below for more insights from AACR 2025. What Are MMRd/MSI-H Tumors? MMRd/MSI-H tumors have defects in DNA mismatch repair, leading to high mutation loads. This makes them more responsive…

Published on May 3, 2025 Antibody-drug conjugates (ADCs) have revolutionized oncology, offering targeted cancer treatments that minimize harm to healthy cells. Over the past 40 years, ADCs have evolved from experimental therapies to a cornerstone of precision medicine, with 11 FDA-approved ADCs and over 210 in clinical trials as of 2024. This article explores the history, mechanisms, challenges, and future of antibody-drug conjugates, drawing from insights published in Cancer Discovery. What Are Antibody-Drug Conjugates? Antibody-drug conjugates are sophisticated therapeutics combining three key components: This design allows antibody-drug conjugates to deliver chemotherapy directly to cancer cells, reducing systemic toxicity compared to…

Introduction Zongertinib (BI 1810631) has shown promising results in treating HER2-mutant non-small cell lung cancer (NSCLC), with a 71% response rate as presented at AACR 2025. This oral, HER2-selective tyrosine kinase inhibitor (TKI) offers a new option for patients with this challenging condition. In this post, we explore the Beamion LUNG-1 trial results, zongertinib’s clinical benefits, and its potential impact on NSCLC treatment protocols. Zongertinib’s Efficacy in HER2-Mutant NSCLC The Beamion LUNG-1 trial revealed zongertinib’s impressive efficacy in previously treated HER2-mutant NSCLC patients. It achieved a 71% objective response rate (ORR). This means 71% of patients experienced tumor shrinkage or…

Introduction The KEYNOTE-689 clinical trial has provided a significant update on pembrolizumab’s role in treating resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Presented at the AACR 2025 Annual Meeting, this Phase 3 study (NCT03765918) evaluates neoadjuvant and adjuvant pembrolizumab alongside standard care. With promising event-free survival (EFS) results, this trial could reshape treatment for head and neck cancer. There is also an upcoming FDA priority review. Let’s dive into the findings. What is KEYNOTE-689? KEYNOTE-689 is a Phase 3, randomized, open-label trial assessing pembrolizumab in 734 patients with resectable stage III/IVA LA-HNSCC. Patients were split into two…

FDA approves Penpulimab-kcqx / Anike The FDA approved Anike (Penpulimab-kcqx) on April 23, 2025, for non-keratinizing nasopharyngeal carcinoma (NPC, WHO type 2/3). This anti-PD-1 IgG1 monoclonal antibody offers a new treatment option for oncologists managing NPC, a cancer prevalent in East and Southeast Asia with incidence rates of 15-50 cases per 100,000. This post explores Anike (Penpulimab-kcqx)’s approval, clinical trial data from Studies AK105-304 and AK105-202, safety profile, dosing, and its role in NPC treatment, as covered in Oncology Tube’s recent video. Anike (Penpulimab-kcqx) Approval and Indications for NPC Anike (Penpulimab-kcqx) is approved for two indications in non-keratinizing NPC: This…

Published: April 21, 2025 | OncologyTube.com A groundbreaking phase III study, published on April 11, 2025, in the Journal of Clinical Oncology, highlights sotorasib plus panitumumab as a potential new standard of care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The CodeBreaK 300 trial (DOI: 10.1200/JCO-24-02026) offers critical insights for oncologists and researchers tackling this challenging molecular subtype. Here, we break down the study’s key findings, clinical implications, and future directions. Overview of the CodeBreaK 300 Trial The CodeBreaK 300 study, led by Filippo Pietrantonio, MD, and colleagues, evaluated sotorasib, a KRAS G12C inhibitor, combined with panitumumab, an EGFR…

The 2025 ASCO guidelines on sentinel lymph node biopsy (SLNB) for early-stage breast cancer are reshaping oncology care. Published in the Journal of Clinical Oncology, these recommendations, backed by extensive clinical trials, aim to reduce unnecessary procedures, lower costs, and address health disparities. Learn about the six key updates, their impact on patients, and how they promote personalized treatment while minimizing complications like lymphedema. Visit OncologyTube.com for more insights.

Date: April 8, 2025 On April 8, 2025, the FDA granted regular approval to nivolumab (Opdivo) combined with ipilimumab (Yervoy) for first-line treatment of unresectable or metastatic MSI-H or dMMR colorectal cancer in adults and pediatric patients aged 12 and older. This landmark decision, grounded in the CHECKMATE-8HW trial, positions dual checkpoint inhibition as a transformative option for this molecular subgroup. Below, we break down the trial’s findings, clinical implications, and safety considerations for oncologists, nurse practitioners, and cancer researchers. CHECKMATE-8HW Trial: Robust Efficacy Data The CHECKMATE-8HW trial enrolled 303 patients with previously untreated MSI-H or dMMR colorectal cancer, with…

April 06, 2025 | By Nataliya Mar, MD, Associate Professor, UC Irvine The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCOGU) 2025 has emerged as a landmark event for oncology, unveiling critical updates in the treatment of genitourinary cancers. These advancements promise to reshape care for patients with prostate cancer, muscle-invasive urothelial carcinoma (MIUC), and muscle-invasive bladder cancer (MIBC). During the symposium, Nataliya Mar, MD – Associate Professor at UC Irvine, presented in-depth analyses of the Telepro 2, CheckMate 274, and Niagara trials, showcasing the potential of therapies like telopera, nivolumab, and durvalumab to improve patient outcomes. This article…

By Samuel Zeng, MD – UCLAPosted on April 4, 2025 When chest pain strikes a patient with a history of heart disease, acute coronary syndrome (ACS) often tops the differential. But as Samuel Zeng, MD, a second-year internal medicine resident at UCLA, discovered in a recent case study, immune checkpoint inhibitors (ICIs) can complicate the picture. In his poster presentation, “ICI-Induced Myocarditis: When Chest Pain Is Not Due to a Blocked Vessel,” Dr. Zeng unravels a rare and lethal complication that challenges conventional thinking. Here’s what clinicians need to know. A Complex Patient Profile The case centers on an 84-year-old…

By: Neil Chawla, MD – Oncologist and Researcher at the Cancer Center of SouthernCalifornia and Sarcoma Oncology Center Introduction to NGS Testing in Sarcoma Care Next-generation sequencing (NGS) is transforming how we approach sarcoma treatment. For patients with this rare cancer, NGS testing is a critical tool that can uncover actionable insights. While its adoption is growing, many patients still arrive at specialized centers without having undergone this testing. Why does this matter, and how is it shaping the future of sarcoma care? Let’s dive into the details. Why NGS Testing Matters for Sarcoma Patients NGS testing analyzes a patient’s…

By: Hamid Mirshahidi, MD – Loma Linda University The AACR 9th Edition has introduced significant changes to the TNM staging system for lung cancer. These updates, effective as of April 2025, reshape how we categorize and treat the disease. They reflect advancements in understanding lymph node involvement and disease progression. This impacts treatment decisions and patient outcomes. Lung Cancer Key Staging Changes These shifts can change treatment plans. For instance, Stage 2B patients (e.g., T1 N2A) might be candidates for preoperative chemo-radiation or immunotherapy rather than surgery alone. Stage 3B or 3C cases may lean toward systemic therapies. Lung Cancer…

By Dr. Bradley McGregor | Published April 02, 2025 Renal cell cancer (RCC) treatment continues to evolve, and Tivozanib (TIVO) is at the forefront of this progress. In a recent analysis, I explored the efficacy and safety exposure-response (ER) of Tivozanib, shedding light on its role as a tyrosine kinase inhibitor (TKI) in RCC management. Here’s what we found—and why it matters for patients and clinicians alike. Building on a Strong Foundation Our analysis didn’t start from scratch. We leveraged pharmacokinetic (PK) models from prior trials, like TIVO-3, which evaluated Tivozanib as a monotherapy. This foundation allowed us to dive…

2025 Leukemia and Lymphoma Updates: Clarkson’s Disease, Myeloma, and MDS Treatments The field of hematology is witnessing remarkable advancements, offering new hope for patients with rare blood disorders and cancers. In a recent discussion hosted by the Medical Oncology Association of Southern California (MOASC) as part of the 2025 Leukemia / Lymphoma Updates, Dr. Aaron Goodman, MD, from UC San Diego, provided an in-depth look at Clarkson’s disease, relapsed diffuse large B-cell lymphoma (DLBCL), multiple myeloma, and low-risk myelodysplastic syndromes (MDS). This comprehensive session highlighted the latest treatment options, their challenges, and the importance of patient-centered care in navigating these…

Introduction: A Milestone Achievement for Dr. Peter Zang Peter Zang, MD, a second-year fellow at City of Hope, has reached a career-defining moment by being named the 2025 Cary Presant, MD Investigator Award winner. Presented by the Medical Oncology Association of Southern California (MOASC) and accompanied by a $25,000 research grant from AVEO Oncology, this honor reflects his relentless dedication. Dr. Zang calls it a “huge deal” after years of pursuing young investigator awards, and it positions him to advance cancer research with real patient impact. At City of Hope, a hub for innovative oncology, he’s ready to make waves…

Date: March 19, 2025 On March 19, 2025, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda, Merck) in combination with trastuzumab and chemotherapy as a first-line treatment for adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval applies specifically to patients whose tumors express PD-L1 with a Combined Positive Score (CPS) of ≥1. This milestone follows an accelerated approval for the same indication in May 2021, now solidified by robust clinical trial data. Video: “Breaking Down the FDA’s Pembrolizumab Approval” [Embedded Video Placeholder]Video Description: A 2-minute animated explainer…

Audio Only: Audio, Video and Slides What’s New in Oncology? – Key Updates from Recent Research Welcome to the latest edition of What’s New in Oncology?, your go-to source for the most current insights in cancer research. This week, we’re diving into groundbreaking studies from the Journal of Clinical Oncology and other leading publications, covering metastatic prostate cancer, breast cancer, lung metastasis, and neuroblastoma. Here’s a detailed breakdown of the latest findings that are shaping the future of oncology. KEYNOTE-921 Trial: Immunotherapy in Metastatic Castration-Resistant Prostate Cancer (MCRPC) A new article from the Journal of Clinical Oncology explores the KEYNOTE-921…

Date: March 11, 2025 Renowned Cancer Researcher Honored in 2025 The American Association for Cancer Research (AACR) and the Pezcoller Foundation proudly announce that Douglas Hanahan, PhD, FAACR, has been awarded the 2025 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research. Hanahan, a Ludwig Distinguished Scholar at the Ludwig Institute for Cancer Research in Lausanne, Switzerland, will be celebrated at the AACR Annual Meeting 2025, held April 25-30 in Chicago. Groundbreaking Contributions to Cancer Science Hanahan’s pioneering work has reshaped cancer research. He co-authored the “Hallmarks of Cancer” with Robert Weinberg, PhD, providing a vital framework for understanding…

LOS ANGELES AACR IO 2025 At a recent oncology session from AACR Immunotherapy 2025, Melissa G. Lechner, MD, PhD, presented findings on the challenges of cancer immunotherapy. She focused on its autoimmune side effects and a newly identified link to bone health. The discussion highlighted the therapy’s expanding role and the need to address its risks as it reaches more patients. The Growing Challenge of Immunotherapy Side Effects Dr. Lechner began by framing the issue: “We had today was talking about immunotherapy and the autoimmune side effects that it can cause unhealthy tissues.” She noted that these effects are common,…

March 4, 2025 New Treatment Option for ESCC Patients The U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) in combination with platinum-containing chemotherapy. This approval is for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1%). The approval, announced on March 4, 2025, offers a new treatment option for this patient group. Dr. Nataliya Uboha, Associate Professor at the University of Wisconsin Carbone Cancer Center, noted, “The approval of TEVIMBRA in combination with chemotherapy for adult patients with ESCC expands first-line treatment options for patients with this disease.…

Katy Beckermann, MD, PhD – Vanderbilt University The phase 3 TiNivo-2 study (NCT04987203), sponsored by AVEO Pharmaceuticals, Inc., recently evaluated tivozanib (TIVO) combined with nivolumab (NIVO) versus TIVO monotherapy in patients with renal cell carcinoma (RCC) who progressed after immune checkpoint inhibitor (ICI) therapy. While the study didn’t meet its primary endpoint of improved progression-free survival (PFS) with the combination, it offers valuable insights into patient-reported outcomes (PROs) and treatment implications. Study Design and Key Findings Patients received either TIVO 0.89 mg + NIVO or TIVO 1.34 mg alone as second-line (2L) or third-line (3L) therapy. PFS results showed:…

A Novel Tyrosine Kinase Inhibitor Poised to Transform Advanced Lung Cancer Care Boehringer Ingelheim | Ridgefield, Conn., and Ingelheim, Germany | February 19, 2025 On February 19, 2025, Boehringer Ingelheim announced that the U.S. FDA has granted Priority Review to zongertinib (BI 1810631), an investigational oral tyrosine kinase inhibitor (TKI) targeting HER2 (ERBB2) mutations in non-small cell lung cancer (NSCLC). This milestone underscores the urgent need for targeted therapies in this molecularly defined subset of lung cancer patients. Indication: Adult patients with unresectable or metastatic NSCLC harboring HER2 (ERBB2) mutations, who have progressed on prior systemic therapy. Mechanism: Zongertinib selectively…

Original Authors:  Luís F Leite da Silva, Erick F Saldanha, Júnior Samuel Alonso de Menezes, Leonardo Halamy Pereira, João Alexandre R de Bragança Dos Santos, Isabella Romagnoli Buonopane, Erito M de Souza, Caio Ulysses Galvani de Menezes, Gilberto Lopes PMID: 39998904 | PMCID: PMC11853598 | DOI: 10.1093/oncolo/oyae344 | Date: March 03, 2025 Abstract Background: Predicting early treatment response in advanced non-small cell lung cancer (NSCLC) is challenging. Longitudinal monitoring of circulating tumor DNA (ctDNA) can track tumor response to treatments like immune checkpoint blockade (ICB) and correlate with outcomes. This meta-analysis evaluated whether ctDNA clearance or decrease is associated with…

Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer Institute Cancer immunotherapy has long been dominated by T cells and immune checkpoint inhibitors. However, a groundbreaking presentation by Jose Ramon Conejo-Garcia, MD, PhD, from Duke Cancer Institute, is shifting the spotlight to an overlooked player: humoral immunity. In a recent talk, Dr. Conejo-Garcia shared how isotype-switched antibodies produced in tertiary lymphoid structures (TLS) could hold the key to antagonizing human cancer progression. This offers new hope for more effective treatments. Here’s what you need to know about this exciting frontier in cancer research. The Power of…

February 26, 2025 | By Michael Karin, Phd Liver cancer, specifically hepatocellular carcinoma (HCC), is on the rise—and a sneaky culprit called Metabolic-Associated Steatohepatitis (MASH) is driving the surge. This inflammatory liver condition, tied to our modern diets, is sparking a scientific revolution. Fresh research from 2025 unveils how fructose-heavy meals, DNA damage, and rogue immune cells are conspiring against us—and how we might fight back with unexpected allies like a common blood pressure drug. Let’s dive into this game-changing science. MASH: The Silent Epidemic MASH is no small-fry health issue. Its incidence is climbing fast, especially in the US…

Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research. This year, Kari L. Kendra, MD, PhD from The Ohio State University delivered a transformative presentation on desmoplastic melanoma (DM). This rare subtype of melanoma is characterized by its presence in high sun-exposed areas with extensive UV damage and a high tumor mutational burden. It is emerging as a pivotal focus in immunotherapy innovation. Dr. Kendra’s insights, shared with a global audience of researchers and clinicians, highlight why DM is achieving unprecedented response rates. They also present what this means…

Los Angeles, February 2025 – The inaugural AACR IO Conference kicked off with an electrifying start, bringing together the world’s leading experts in immunotherapy for a groundbreaking event in downtown Los Angeles. This vibrant gathering showcased the best minds in the field. They delivered two unforgettable keynote sessions that set the stage for innovation in cancer research. Highlights from the Keynotes A Collaborative Hub for Immunotherapy AACR IO 2025 is designed to unite diverse backgrounds—spanning vaccines, immune response modeling, cytokines, cell therapies, and cell engineering. This interdisciplinary approach creates a dynamic and exciting platform for sharing ideas. It drives progress…

Could 2025 Oncology Have Saved Steve Jobs from Pancreatic Cancer? A Deep Dive into Past and Future Treatments February 21, 2025 | By OncologyTube Steve Jobs Death marked the end of an era, but his influence on technology remains undeniable. The genius behind Apple left an indelible mark on technology—but his battle with pancreatic neuroendocrine tumor (pNET) cut his journey short in 2011. Diagnosed in 2003, Jobs faced a rare form of pancreatic cancer with a better prognosis than most, yet his choices—delaying conventional treatment for alternative therapies—and the limited options of the time couldn’t stop the disease’s progression. But…

MRI’s Role in Prostate Cancer Diagnosis – A 3-Year Study Breakthrough Date: February 20, 2025 Prostate cancer, the second most common cancer in men globally, has long relied on PSA tests and digital rectal exams (DRE), often leading to invasive biopsies. But what if an MRI could safely spare men from this procedure? A groundbreaking 3-year cohort study published in JAMA Oncology (December 12, 2024) offers compelling evidence that it can. Led by Dr. Charlie A. Hamm at Charité–Universitätsmedizin Berlin, this research redefines prostate cancer diagnosis with prebiopsy multiparametric MRI (mpMRI). Here’s what you need to know. The Study at…

FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On January 27, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki—better known as Enhertu—for patients with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer. This approval marks a significant step forward, offering new hope to those whose cancer has progressed after endocrine therapy. Developed by Daiichi Sankyo, Inc., Enhertu is the first therapy specifically approved for HER2-ultralow breast cancer, expanding treatment options for a previously underserved group. Who Does Enhertu Help? Enhertu targets adults with hormone receptor-positive…

On February 14, 2025, the U.S. Food and Drug Administration (FDA) delivered a Valentine’s Day gift to patients battling symptomatic tenosynovial giant cell tumor (TGCT): the approval of vimseltinib (Romvimza), a novel kinase inhibitor developed by Deciphera Pharmaceuticals, LLC. This marks a significant milestone for adults with TGCT—a rare tumor affecting joints and tendons—especially in cases where surgery could worsen function or cause severe morbidity. What is TGCT, and Why Does This Matter? Tenosynovial giant cell tumor is an uncommon condition that can lead to pain, swelling, and restricted movement. For many patients, surgical removal is the go-to treatment, but…

Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At the 2025 ASCO Genitourinary Cancers Symposium, the latest findings from the EV-302 study were presented, providing an updated analysis on the efficacy of combining enfortumab vedotin with pembrolizumab (EV+P) versus standard chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). Key Points from the Enfortumab Vedotin EV-302 study: Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of London, highlighted the importance of these findings, stating, “Enfortumab vedotin is the first…

Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in MIBC Date: February 14, 2025 Author: Dr. Matthew I. Milowsky, MD, FASCO, University of North Carolina School of Medicine Key Points: Quotes: Continued DFS Benefit: The CheckMate-274 trial, a phase 3 study, had previously established a significant DFS benefit with adjuvant nivolumab: Promising OS Trend: PD-L1 Expression and OS: Safety Profile: Future Directions: Conclusion: Dr. Milowsky concluded, “The fact that the study continues to demonstrate significant improvement in disease-free survival, and that this interim overall survival data looks very promising, is very exciting.” Note: This post aims to consolidate and present…

Transforming MIBC Treatment: Insights from the NIAGARA Trial Posted on February 16, 2025 The landscape of treating muscle-invasive bladder cancer (MIBC) has potentially shifted with the latest insights from the phase III NIAGARA trial. Here’s a concise overview of what you need to know: Understanding MIBC: NIAGARA Trial Highlights: Clinical Implications: Conclusion & Future Directions: Durvalumab has shown promising results in enhancing survival outcomes for MIBC. However, future studies need to consider comparisons with potentially outdated chemotherapy regimens. The path forward includes integrating these findings into clinical practice and refining the treatment approach for even better patient outcomes. Stay tuned…

Talazoparib + Enzalutamide Introduction: We are excited to share the latest findings from the TALAPRO-2 Trial, which marks a significant advancement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Here’s a deep dive into what this means for patients and the medical community. TALAPRO-2 Study Overview: The TALAPRO-2 study is a Phase 3 clinical trial that has set out to evaluate the efficacy of combining Talazoparib with Enzalutamide compared to Enzalutamide alone for patients newly diagnosed with mCRPC. This study aims to set new standards in first-line treatment approaches. Background on mCRPC Treatment: mCRPC represents a challenging stage of…

Date: February 12, 2025 FDA Approves Adcetris Overview The FDA has approved a new combination therapy for adults with relapsed or refractory Large B-cell Lymphoma (LBCL) on February 11, 2025. This therapy combines Brentuximab Vedotin (Adcetris), Lenalidomide, and Rituximab and is intended for patients who have undergone at least two prior systemic therapies and are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy. Key Details of the Approval: This approval provides an additional treatment option for LBCL patients. For more detailed information, the full prescribing guide will be available on Drugs@FDA. Clinical Practice Implications: This…

FDA Approves Mirdametinib for NF1-PN: A New Option for Patients Introduction: The FDA has recently approved Mirdametinib (Gomekli) from SpringWorks Therapeutics for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) in patients aged 2 years and older. This approval is based on the outcomes of the phase 2b ReNeu clinical trial. The approval offers new hope and options for managing this condition. Below is a detailed look at the drug’s approval, trial results, and implications. The Approval: Efficacy: Treatment Regimen: Eligibility and Safety: Key Takeaways: Looking Forward: Conclusion: The FDA’s approval of Mirdametinib marks an addition to therapeutic options…

MOASC: Medical Oncology Association of Southern California Welcome to MOASC’s Digital Presence on OncologyTube The Medical Oncology Association of Southern California (MOASC), established in 1990, is dedicated to advancing and protecting the ability of cancer patients to receive optimal care, while empowering oncology physicians to provide it. Representing over 600 hematologists/oncologists across Southern California, from community practices to academic centers like UC Irvine, UC San Diego, and the University of Southern California, MOASC serves as a pivotal resource for its members. Our Vision MOASC’s vision is clear: to ensure continued access to top-tier cancer care. Through our YouTube channel on…

Date: February 8, 2025 The U.S. Food and Drug Administration (FDA) has recently granted approval for datopotamab deruxtecan (DLNK), a new treatment option for adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This marks a significant advancement in the fight against breast cancer, particularly for those who have progressed after prior endocrine-based therapies. Key Points: This approval provides hope and an additional therapeutic avenue for patients facing advanced stages of this type of breast cancer, potentially improving outcomes where previous treatments have failed. For more detailed information, including clinical trial data,…

Dive into the groundbreaking results of the EMBER-3 Phase 3 trial (NCT04975308) as presented by Dr. Virginia Kaklamani from UT Health San Antonio at the San Antonio Breast Cancer Symposium (SABCS). This trial focuses on imlunestrant, an innovative oral Selective Estrogen Receptor Degrader (SERD) specifically designed for patients with ER+, HER2- Advanced Breast Cancer (ABC) who have already been treated with endocrine therapy. Key Findings from the EMBER-3 Trial: What Does This Mean for Patients? Watch our video for an in-depth discussion on these findings, what they could mean for the future of breast cancer treatment, and how they might…

Overview: The results from the Phase 3 CheckMate-8HW trial have just been released, demonstrating significant improvements in outcomes for patients with metastatic colorectal cancer (mCRC) exhibiting high-level microsatellite instability or deficient mismatch repair (MSI-H/dMMR). This study marks the first direct comparison between dual and single-agent immunotherapy in this patient population. Key Findings: Study Details: Implications for Practice: Next Steps: Download Slides Here: Hashtags: #CheckMate8HW #Nivolumab #Ipilimumab #MSIH #dMMR #ColorectalCancer #mCRC #CancerResearch #Oncology #Immunotherapy #ClinicalTrials Note: This post is for informational purposes and should not replace consultation with healthcare professionals for treatment decisions. Related Articles: https://dailynews.ascopubs.org/do/checkmate-8hw-nivolumab-ipilimumab-demonstrates-improved-outcomes-over-standard

Abstract: Circulating tumor DNA (ctDNA) has a short half-life (<2 hours) which may permit real-time monitoring of tumor status. This single-institution study aimed to assess the feasibility of rapid treatment response evaluation through serial short-interval ctDNA testing. Patients with gastrointestinal (GI) cancer undergoing immune checkpoint inhibitor (ICI)-based therapy were included. A personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc.) was used to measure changes in ctDNA levels between the first cycle (C1D1) and the second cycle (C2D1). The study found a strong correlation between ctDNA kinetics and treatment response in 86% of cases. This suggests that this method could guide treatment…

In the rapidly evolving field of cancer treatment, the application of comprehensive genomic profiling (CGP) via liquid biopsy has become a pivotal tool for tailoring therapies in metastatic biliary tract cancer (mBTC). A recent study using real-world data from the GuardantINFORM database sheds light on the effectiveness of first-line treatments in patients with specific genetic mutations. Background: Historically, the first-line treatment for mBTC has been gemcitabine-cisplatin (GemCis) with or without immunotherapy (IO), such as durvalumab or pembrolizumab. However, this study questions the universal applicability of this approach, particularly for patients with IDH1 mutations or FGFR2 fusions. Study Insights: The research…

In the evolving landscape of cancer care In the evolving landscape of cancer care, the use of circulating tumor DNA (ctDNA), also known as liquid biopsies, is becoming increasingly significant in the management of colorectal cancer. This is true regardless of the stage at diagnosis. Recent discussions and studies have shed light on how ctDNA can guide treatment decisions, particularly in patients with stage II and III colorectal cancer. For stage II colorectal cancer patients, the decision to administer adjuvant chemotherapy is nuanced and complex. It involves a detailed review of the pathology report and multiple risk factors. It’s important…

BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Really Lead to Longevity Leaps? Text: @OncoAlert @oncology @BreastCancerNow @SABCS @ProfMatteoLambertini #SABCS24 #BRCA #CancerPrevention #BreastCancerSurvival #RiskReducingSurgery #OncologyResearch #BRCAmutation… pic.twitter.com/2XZofthBCC— Oncology Tube (@oncologytube) December 17, 2024 Introduction: Prof. Matteo Lambertini presented the findings from the international BRCA BCUI collaboration study during SABCS 2024. The study focuses on the impact of risk-reducing surgeries in young BRCA mutation carriers with a history of breast cancer. “The risk of relapse of the primary breast cancer should be balanced with the risk of developing a second primary malignancy.” – Prof. Matteo Lambertini Background: BRCA gene mutations are…

Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results Text Version: @DFCI_BreastOnc @Otto_DFCI @OncoAlert @PfizerIbrance @pfizer_news @SABCSSanAntonio @AACR #SABCS24 #Palbociclib #IBRANCE #PATINAStudy #MetastaticBreastCancer #ERHER2Positive #CDK46Inhibitors… pic.twitter.com/WkCCM22flL— Oncology Tube (@oncologytube) December 17, 2024 Update on the PATINA Phase 3 Study: Palbociclib in ER+/HER2+ Metastatic Breast Cancer Approximately 20% of breast cancers overexpress HER2, with 50% of these patients also expressing the estrogen receptor. While anti-HER2 therapies have improved survival outcomes, resistance remains a significant challenge. The rationale for using CDK4/6 inhibitors like palbociclib in HER2-positive disease stems from known benefits in ER-positive settings. The PATINA study, a phase 3 trial,…

We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.

“So basically, we looked at two factors, the one saying the long term remission of heart positive metastatic breast cancer patients treated with trastuzumab based therapy. We specifically looked at some of those that had prolonged remission for more than five years.” – Dr. Aydah Al-Awadhi In an enlightening deep dive into the world of oncology, Dr. Aydah Al-Awadhi shares insights from a single-center retrospective analysis focused on the factors contributing to long-term remission in patients with HER2-Positive Metastatic Breast Cancer treated with Trastuzumab-based therapy. Study Overview: Clinical Implications: This study not only sheds light on the predictors of long-term…

In his analysis, Paolo Tarantino, MD, delves into the transformative potential of CDK4/6 inhibitors in breast cancer therapy. He questions whether these drugs, celebrated for their promise in clinical trials, have truly matched expectations in real-world scenarios, specifically referencing data from the NATALEE and monarchE trials. The discussion is visually represented by a superhero figure donning a CDK4/6 emblem, symbolizing the hope and power these inhibitors bring to the fight against breast cancer. This image captures the essence of current medical debates surrounding the efficacy and application of these treatments in managing breast cancer recurrence and overall patient outcomes.

The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.

The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU® (Trastuzumab Deruxtecan, T-DXd) versus physician’s choice of chemotherapy in hormone receptor-positive metastatic breast cancer patients. Study Overview: Dr. Aditya Bardia presented the findings from DESTINY-Breast06, a Phase 3 trial that included patients with HER2-low and HER2-ultra-low metastatic breast cancer who progressed rapidly on prior first-line endocrine therapy. Patients were randomized to receive either ENHERTU® or standard chemotherapy options. Key Findings: Safety Profile: Quality of Life: The study indicated that ENHERTU® could potentially enhance quality of life by controlling disease progression,…

EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer Treatment The results of the Phase 3 EMBER-3 trial were unveiled at the SABCS 2024 conference, presenting critical insights into advanced breast cancer treatment. This global, open-label trial investigated the efficacy and safety of Imlunestrant, an oral endocrine therapy, for ER-positive, HER2-negative advanced breast cancer patients. Key Trial Overview: The study included 874 participants who were divided into three treatment arms: The trial assessed progression-free survival (PFS) as the primary endpoint, alongside secondary and exploratory outcomes such as overall survival and biomarker analysis. Results Summary: Safety and Tolerability: Implications: The trial underscores…

Overview of the CONFORM™ Platform The CONFORM™ platform by EDETEK offers a multifaceted approach to managing clinical data, focusing on five core areas: Oncology-Focused Accelerator: CONFORM™ – ONCO+ For oncology, which presents unique challenges due to its data complexity, EDETEK introduced CONFORM™ – ONCO+. This accelerator: Broader Application and Adoption While CONFORM™ – ONCO+ is focused on oncology, the CONFORM™ platform supports a wide array of therapeutic areas, including CNS, rare diseases, and cardiovascular, and is trusted by half of the top pharmaceutical companies and numerous smaller to mid-size entities. This wide adoption underscores its versatility and impact across the…

The GALAXY Study has provided compelling data that highlights the predictive value of circulating tumor DNA (ctDNA) status in colorectal cancer outcomes. Using Natera’s Signatera test, this study offers oncologists key insights into how ctDNA can be used to monitor disease recurrence, guide therapy decisions, and potentially redefine patient management strategies. Study Design and Participants This large-scale study involved 2,240 patients with stage 2 to stage 4 colorectal cancer (CRC). The median follow-up period was 23 months, and the study focused on the predictive role of ctDNA status in assessing disease-free survival (DFS) and overall survival (OS). The Signatera test,…

The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic malignant pleural mesothelioma (download slides below). This marks the first new treatment for mesothelioma in over 15 years, providing a new option for patients battling this aggressive disease. Key Results from the KEYNOTE-483 Trial The approval was based on findings from the KEYNOTE-483 trial, a randomized, open-label, phase 3 study involving patients with unresectable, advanced, or metastatic malignant pleural mesothelioma who had not received prior systemic therapy. Participants were randomized to receive either pembrolizumab with pemetrexed and platinum-based chemotherapy for…

The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage HR+/HER2- breast cancer in patients at high risk of recurrence (download slides below). This approval provides a new treatment option for patients, aiming to reduce the likelihood of cancer recurrence during the early stages of the disease. Key Findings from the NATALEE Trial The NATALEE trial was a randomized, open-label, multicenter phase 3 trial that included 5,101 adults with HR-positive, HER2-negative early breast cancer. Patients were selected based on lymph node involvement or tumor size and grade, ensuring a diverse…

iTeos Therapeutics and GSK revealed promising results from their phase 2 TIGIT trial at the 2024 European Society for Medical Oncology (ESMO) conference in Barcelona. The mid-stage trial, known as GALAXIES Lung-201, evaluated the combination of belrestotug, an anti-TIGIT antibody, and dostarlimab (Jemperli), GSK’s anti-PD-1 treatment, in patients with previously untreated, unresectable, or metastatic PD-L1-high non-small cell lung cancer (NSCLC). The results demonstrated a 30% improvement in tumor shrinkage with the combination therapy compared to dostarlimab monotherapy. The overall response rate (ORR) was impressive across all dosing cohorts: These results stand in contrast to the 37.5% ORR for patients who…

On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of a PD-(L)1 inhibitor for cancer treatment. Developed by Genentech, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) allows for a 7-minute subcutaneous injection, significantly reducing the 30 to 60 minutes typically required for intravenous (IV) administration of Tecentriq. This new formulation provides an alternative treatment option for patients with cancers such as non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and others. New Administration Option for Cancer Patients Tecentriq Hybreza is expected to offer patients and healthcare providers…

On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy for use as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant therapy, in adults with resectable non-small cell lung cancer (NSCLC). This approval applies to patients with tumors measuring 4 cm or greater and/or node-positive disease, excluding those with known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. Key Findings from the AEGEAN Trial The approval was based on efficacy data from the AEGEAN trial (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial involving 802 patients with…

AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17. The oral presentation will provide key results from the TiNivo-2 clinical trial, which evaluated the efficacy and safety of combining nivolumab, a PD-1 checkpoint inhibitor, with FOTIVDA® (tivozanib), a VEGFR tyrosine kinase inhibitor (TKI). The study compared the effects of this combination to standard dose tivozanib monotherapy in patients with metastatic renal cell carcinoma (RCC) who had progressed after…

By: Nathalie M. Johnson, MD – Legacy Health Partners Conference: ASBrS Dr. Nathalie M. Johnson, MD, a breast cancer specialist with Legacy Health Partners, delves into the evolving role of circulating tumor DNA (ctDNA) in the management of breast cancer. As the field of oncology continues to advance, Dr. Johnson emphasizes the importance of adopting ctDNA testing more widely to improve patient outcomes, particularly for those with high-risk breast cancer types. The Role of ctDNA in Breast Cancer Management Dr. Johnson begins by highlighting how ctDNA is becoming a crucial tool in her practice. Although there aren’t standardized guidelines for…

By: Dr. Kevin Hughes, MD, from MUSC Health Conference: ASBrS Introduction Dr. Kevin Hughes, MD, from MUSC Health, sheds light on a critical issue in the field of oncology: the underutilization of genetic testing among patients who could significantly benefit from it. Despite the availability of commercial genetic testing for the past 25 years, an astonishing 90% of patients with genetic mutations remain unaware of their status. This lack of awareness often leads to missed opportunities for early intervention and cancer prevention. The Problem with Current Genetic Testing Practices Dr. Hughes points out that many patients with mutations that could…

Introduction On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or metastatic synovial sarcoma. This approval marks a significant advancement in immunotherapy for synovial sarcoma, a rare and aggressive cancer type. TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy. This treatment is specifically for patients who have previously undergone chemotherapy and whose tumors express the MAGE-A4 antigen. Clinical Trial and Efficacy The approval was based on the results from the SPEARHEAD-1 trial, a multicenter, single-arm, open-label study. This trial included patients with inoperable or metastatic synovial…

On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination with carboplatin and paclitaxel, for adult patients with primary advanced or recurrent endometrial cancer. This new approval allows the use of dostarlimab-gxly not only in mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) patients but also in the broader population of those with primary advanced or recurrent endometrial cancer. Clinical Trial Evidence The approval was based on the results of the RUBY trial (NCT03981796), a randomized, multicenter, double-blind, placebo-controlled study involving 494 patients. Participants were randomized to receive either dostarlimab-gxly…

Introduction ASCO 2024 Head & Neck Cancer developments brought forth several anticipated studies. These studies in the field of head and neck cancer showcase advancements that could potentially change clinical practices. Dr. Shlomo Koyfman, MD, highlighted three pivotal studies that stood out during the conference. These studies delve into proton therapy, biomarker trials, and the role of immunotherapy. They offer new insights and potential changes in treatment approaches for head and neck cancer patients. 1. IMRT vs. IMPT Proton Therapy Study The much-anticipated IMRT (Intensity-Modulated Radiation Therapy) versus IMPT (Intensity-Modulated Proton Therapy) phase three study finally provided data after a…

By: Dr. Erica Giblin, MD, from Ascension Medical Group Conference: ASBrS Genetic Testing Cancer In recent years, the field of oncology has witnessed significant advancements, particularly in the realm of genetic testing. One such advancement is the use of circulating tumor DNA (ctDNA) monitoring. This has the potential to revolutionize cancer treatment and management. Dr. Erica Giblin, MD, from Ascension Medical Group, shares her insights and experiences with ctDNA testing. She highlights its impact on the detection and treatment of breast cancer recurrences. The Role of ctDNA in Early Detection Dr. Giblin emphasizes the importance of ctDNA monitoring, noting that…

By: Barry S. Rosen, MD – Advocate Aurora Health Conference: ASBrS 2024 In the evolving landscape of cancer treatment, ctDNA (circulating tumor DNA) testing has emerged as a pivotal tool in managing advanced cancers. In this insightful post, Dr. Barry Rosen, MD, shares his experiences and perspectives on using ctDNA testing, specifically the Signatera test, to detect molecular residual disease. This post highlights the key points from his discussion and explores the potential impact of ctDNA testing on treatment decisions. Signatera Test and Its Implementation: Dr. Rosen recalls that the Signatera test received commercial approval approximately two and a half…

Introduction: In a comprehensive presentation, Dr. Jacob Sands, MD, a medical oncologist, delves into the treatment options for small cell lung cancer (SCLC). He primarily discusses the use of Lurbinectedin and Irinotecan, both standard regimens in SCLC management. This discussion covers their individual and combined usage, potential synergy, clinical trial data, and their place in the current treatment paradigm. Chapters: 0:00:00 – Introduction: Standard Regimens for Small Cell Lung Cancer 0:01:00 – Enrollment Criteria and Patient Characteristics ‘0:02:00 – Second Line Treatment Options 0:03:00 – Synergy in Combination Therapy 0:04:00 – Adverse Events and Toxicity Management 0:05:00 – Encouraging Results…

Author: Dr. Shubham Pant, MD – MD Anderson Overview: At the ASCO 2024 conference, Dr. Shubham Pant, MD – MD Anderson shared exciting updates from the Phase 2 trial of zanidatamab, a bispecific HER2 antibody, in patients with HER2-positive biliary tract cancer (BTC). This trial highlights the potential of zanidatamab to improve treatment outcomes for this challenging cancer type. Mechanism of Action: Zanidatamab targets two domains on the HER2 protein (ECD2 and ECD4), which enhances receptor internalization and HER2 downregulation. This dual targeting mechanism leads to a more effective antitumor response compared to traditional HER2-targeted therapies. Study Design: Key Findings:…

Author: Dr. Zandra Klippel, Global Product Head, Multiple Myeloma, Sanofi At the ASCO 2024 conference, Dr. Zandra Klippel the Global Product Head, Multiple Myeloma, Sanofi summarizes the promising Phase 3 results from the IMROZ study. This study evaluated the combination of Sarclisa (isatuximab) with VRd (bortezomib, lenalidomide, and dexamethasone) in patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant. Key Findings: Future Research Directions: Ongoing research aims to optimize dosing, reduce side effects, and expand the use of Isa-VRd to other myeloma populations, including those eligible for transplant. Future trials will explore different dosing schedules and delivery…

Author: Dr. Alexis LeVee, City of Hope At the ASCO 2024 conference, Dr. Alexis LeVee from City of Hope presented a pivotal Phase 1b clinical trial that explores the combination of CDK4/6 inhibitors and PD-1 inhibitors with endocrine therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC). This study investigates how these combinations can enhance anti-tumor responses and improve clinical outcomes. Study Details: Results: Conclusion: The combination therapy shows promising results in enhancing immune response and improving clinical outcomes in HR+/HER2- mBC patients. Further evaluation in prospective trials is needed to confirm these findings. Abstract: A phase…

Author: Dr. Regina Barragan-Carillo, City of Hope Overview: At ASCO 2024, Dr. Regina Barragan-Carillo from City of Hope Cancer Center shared her pioneering research on how Latino ethnicity influences the gut microbiome composition in patients with metastatic renal cell carcinoma (mRCC). This study sheds light on the crucial link between ethnicity, gut microbiome, and treatment outcomes with immune checkpoint inhibitors. Study Highlights: Implications: This study emphasizes the importance of considering ethnic diversity in medical research and treatment strategies. Understanding the unique gut microbiome profiles of different ethnic groups can lead to more personalized and effective cancer treatments. Conclusion: Dr. Barragan-Carillo’s…

Presented by Dr. Hedyeh Ebrahimi, City of Hope Overview: At the ASCO 2024 conference, Dr. Hedyeh Ebrahimi of City of Hope presented an impactful study led by Dr. Alex Chehrazi Rafel. The study investigated the effectiveness of high-dose chemotherapy regimens in patients with recurrent germ cell tumors. This collaborative effort included contributions from four leading referral centers: City of Hope, UCSF, UC Davis, and UCLA. Study Details: Key Findings: Implications: The results highlight the potential benefits of the TICE regimen for improving overall survival in patients with recurrent germ cell tumors. Additionally, the identification of beta HCG as a prognostic…

… Dr. Sumanta (Monty) Kumar Pal, M.D., FASCO highlights some of the top data and presentations being presented in kidney and bladder cancer from ASCO 2024 annual meeting in Chicago. Below are 4 links to the data which was highligted: Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.https://meetings.asco.org/abstracts-presentations/231606 Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).https://meetings.asco.org/abstracts-presentations/231607 Biomarker…

Dr. Omid Hamid from The Angeles Clinic goes over his favorite presentations coming up at ASCO 2024. Should these be on your short list too? … Christian U. Blank – Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.https://meetings.asco.org/abstracts-presentations/234897 Jeffrey S. Weber – Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.https://meetings.asco.org/abstracts-presentations/233031 Sajeve Samuel Thomas – Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202…

Introduction During a comprehensive presentation by Dr. Catherine Coombs at UC Irvine, insights into the unique challenges and opportunities of using CAR T-cell therapies in Chronic Lymphocytic Leukemia (CLL) were discussed. Despite CLL being a malignancy with numerous effective treatment options, CAR T-cell therapy has been relatively slow to gain approval. This detailed exploration highlights the potential and hurdles of integrating CAR T into CLL management, including a review of Lysacel and other significant treatments. The State of CAR T in CLL Challenges in CLL Dr. Coombs pointed out that CLL is characterized by immune dysfunction, which can impair the…

Introduction At a recent conference, Dr. Anjali Advani of the Cleveland Clinic discussed the transformative role of Chimeric Antigen Receptor T-cell (CAR-T) therapy in the treatment of acute lymphoblastic leukemia (ALL), especially in conjunction with bispecific antibodies and antibody-drug conjugates. Her talk offered a comprehensive overview of current therapies and explored the future of CAR-T in ALL treatment, providing crucial insights for oncologists. The Evolution of ALL Treatment Current Landscape Historically, adults with relapsed refractory ALL had dismal prognoses, but the landscape has shifted dramatically with the introduction of innovative therapies. Dr. Advani highlighted four pivotal agents currently approved for…

Introduction During the CAR-T & Bispecifics Conference, Dr. Brian Sworder, MD, from UCI Irvine, shared compelling insights on the utility of circulating tumor DNA (ctDNA) in the context of CAR-T cell therapy, particularly for relapsed refractory large B-cell lymphoma. This summary highlights the critical aspects of his presentation, emphasizing the revolutionary potential of ctDNA in predicting therapy outcomes and understanding resistance mechanisms. The Significance of Circulating Tumor DNA in Oncology Understanding ctDNA Circulating tumor DNA consists of small fragments of DNA shed by tumor cells into the bloodstream. It serves as a non-invasive biomarker that can be analyzed to detect…

Introduction During the recent CAR-T & Bispecifics conference, Dr. Nitin Jain, MD, from MD Anderson Cancer Center in Houston, Texas, presented a challenging case involving advanced B-cell lymphoblastic leukemia (BLL). This discussion offered profound insights into the nuanced decision-making processes in oncology, particularly in cases involving genetic complexities and multiple treatment failures. The session highlighted the evolving landscape of oncological treatment where genetic insights drive personalized medicine approaches. … Detailed Case Review and Genetic Implications Patient Background The focus was on a 25-year-old Hispanic male patient initially diagnosed with BLL in 2016. This patient’s medical journey has been significantly complicated…

Introduction The recent findings from the DESTINY-Breast06 Phase III trial signify a potential shift in the treatment landscape for HR-positive, HER2-low metastatic breast cancer. This landmark study evaluates the efficacy of Enhertu (trastuzumab deruxtecan), a specifically engineered antibody drug conjugate, marking significant strides in targeted cancer therapy. These results demonstrate substantial improvements in progression-free survival (PFS) compared to standard chemotherapy, offering new hope for patients with limited treatment options. Trial Design and Methodology Overview DESTINY-Breast06 is a global, randomized, open-label, Phase III trial that compares the effectiveness and safety of Enhertu against the investigator’s choice of standard chemotherapy, which includes…

Introduction The US Food and Drug Administration (FDA) recently approved nogapendekin alfa inbakicept-pmln (Anktiva), used in conjunction with bacillus Calmette-Guérin (BCG), marking a significant advancement in the treatment of non–muscle-invasive bladder cancer (NMIBC) unresponsive to BCG alone. This groundbreaking approval addresses a substantial unmet need within the high-risk bladder cancer population, offering new hope for thousands of patients across the United States. Background and Rationale Bladder cancer ranks as the sixth most prevalent cancer in the United States, with approximately 81,000 new cases annually and 17,000 deaths. NMIBC represents about 70% of all bladder cancer cases and is typically managed…

… Gabriel Mannis, MD Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine provides an in-depth analysis of Notable Lab’s Predictive Precision Medicine Platform. Dr. Mannis discusses the pivotal role of PPMP in advancing the treatment of Acute Myeloid Leukemia (AML), focusing on how its rapid and personalized approach can significantly enhance patient outcomes by tailoring therapies to individual needs. For more information visit www.NotableLabs.com For More Information Visit Notable Lab’s Predictive Precision Medicine Platform

Dr. Charles Link recently discussed the innovative SYNC-T technology (Syncromune® Inc.) during a phase one trial targeting hormone-refractory prostate cancer—a particularly challenging patient group. This post delves into the key aspects and outcomes of this trial, highlighting its significance in the field of oncology. … SYNC-T Technology: A Novel Approach from Syncromune® Inc. SYNC-T technology is an advanced treatment method that integrates a personalized vaccine with a multi-component biologic to target the immune system at the site of the tumor. This process involves directly injecting the tumor site, freezing part of the tumor to release antigens, and simultaneously infusing a…

Introduction to Emerging Therapies in ALL Management … Dr. Elias Jabbour shared recent developments in the treatment of acute lymphoblastic leukemia (ALL) during a recent medical conference. His presentation focused on the evolving landscape of ALL therapy, particularly emphasizing the growing importance of targeted therapies including bispecific antibodies, antibody-drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs). The integration of these therapies is reshaping the standard treatment protocols, potentially reducing reliance on conventional chemotherapy and transplantation. The Role of Tyrosine Kinase Inhibitors (TKIs) A significant portion of the session was dedicated to discussing the effectiveness of TKIs. Dr. Jabbour outlined the…

… The field of oncology is continuously evolving, with research focusing on developing more effective and personalized treatment modalities. One such significant stride in this direction is the KRYSTAL-1 study, which explores the efficacy and safety of combining adagrasib (MRTX849) with cetuximab in treating patients with metastatic colorectal cancer (CRC) harboring the KRASG12C mutation. This article delves into the study’s findings, its implications for clinical practice, and future research directions. Overview of the KRYSTAL-1 Study The KRYSTAL-1 study is a multicenter, phase 1/2 clinical trial that investigates the combination of adagrasib, a KRASG12C inhibitor, and cetuximab, an EGFR inhibitor, in…

… Pancreatic cancer, notorious for its lethality and late-stage diagnosis, presents significant challenges in oncological treatment and patient survival. Dr. Ajay Goel’s recent research introduces a transformative approach to early cancer detection through a blood-based liquid biopsy, leveraging microRNAs and exosomes for unparalleled accuracy. This article delves into the study’s methodology, findings, and its profound implications for the future of oncology. Early Detection: A Paradigm Shift Dr. Goel’s study addresses a critical issue in pancreatic cancer treatment—the disease’s diagnosis at an advanced stage, rendering it inoperable and drastically reducing survival chances. The research aims to circumvent this through early detection,…

… Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. The discovery of specific mutations within NSCLC, such as those in the KRAS gene, has paved the way for targeted therapies. However, tumors harboring KRAS mutations, especially those with concurrent STK11 and KEAP1 mutations, have shown a worse prognosis due to their resistance to current therapies, including chemotherapy and immunotherapy. The work of Triparna Sen, PhD, sheds light on a novel therapeutic target, Stearoyl-CoA Desaturase 1 (SCD1), which plays a pivotal role in the metabolic rewiring of…

… Multiple myeloma, an incurable cancer affecting plasma cells in the bone marrow, continues to challenge the medical community. The search for more effective treatments has led to the development of innovative therapies targeting specific mechanisms involved in cancer progression. A significant breakthrough in this quest is Linvoseltamab, a BCMA CD3 bispecific antibody, which has shown promising results in relapsed and refractory multiple myeloma patients. Sundar Jagannath, MD, presented compelling data at the AACR, highlighting the efficacy and safety of this fully human antibody, which marks a potential paradigm shift in the treatment approach to multiple myeloma. Efficacy of Linvoseltamab…

… Introduction Small cell lung cancer (SCLC) is notoriously aggressive and challenging to treat, with current therapies often providing limited benefit due to the cancer’s rapid progression and recurrence. The search for more effective treatments has led to the exploration of combining traditional chemotherapies with immunotherapies to harness the body’s immune response against tumor cells. A promising development in this field is the use of Lurbinectedin, a therapy initially approved for second-line treatment of SCLC, which has shown potential in not only directly combating tumor cells but also in enhancing the efficacy of immunotherapy agents. The Mechanism of Lurbinectedin Lurbinectedin…

… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing a platform for groundbreaking research, discussions, and recognition of young talent in the field. Dr. Sumanta Kumar Pal, MD known as Monty, took a moment to reflect on the successes of this year’s summit, marking significant milestones and achievements that pave the way for future advancements in cancer research and treatment. Launch of the Young Investigator Award A highlight of MOASC 2024 was the inauguration of the Young Investigator Award, a commendable initiative sponsored by Aveo, aimed at acknowledging and…

The MOASC represents a prestigious accolade designed to recognize and encourage promising young researchers in the field of oncology. This award seeks to highlight individuals who have demonstrated exceptional potential through their innovative research, contributions to oncology, and commitment to advancing cancer care. Awardees are selected based on the novelty, impact, and scientific merit of their work, showcasing groundbreaking findings that could lead to significant advancements in the diagnosis, treatment, and understanding of cancer. The recognition not only celebrates the achievements of these emerging leaders in oncology but also aims to foster their career development, providing support and visibility within…

… At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a leading figure in medical oncology at Cedars-Sinai, Los Angeles, CA, provided a comprehensive update on the transformative approaches in the perioperative management of non-small cell lung cancer (NSCLC). With a distinguished career marked by contributions to advancing treatment modalities, Dr. Reckamp’s insights into the integration of immunotherapy and targeted therapy in NSCLC offer valuable perspectives for oncologists navigating this evolving landscape. Oncogenic Drivers and Treatment Evolution in NSCLC The journey of NSCLC treatment has been significantly influenced by the understanding of oncogenic drivers and…

… Melanoma treatment has significantly evolved due to extensive research and the introduction of novel therapeutic options. Dr. Justin T. Moyers from The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, presented a detailed update on March 6, 2024, providing oncologists with the latest data and clinical insights into melanoma management. Key Studies and Approved Treatment Combinations CHECKMATE-067: Establishing a New Standard CHECKMATE-067 compared the effectiveness of nivolumab alone, nivolumab plus ipilimumab, and ipilimumab alone in patients with unresectable stage III or IV melanoma. This trial identified the combination of nivolumab and ipilimumab as superior in terms of progression-free survival…

… The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of groundbreaking studies and novel therapeutic agents. This detailed review, drawing from a presentation by Elizabeth Brem, MD, at the University of California, Irvine, delves into the significant strides made in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) treatment. It examines pivotal trials, compares therapeutic strategies, and discusses their implications for current clinical practice, offering oncologists a roadmap for integrating these innovations into patient care. Hodgkin Lymphoma: Evolving Standards and New Horizons Revisiting ECHELON-1: A Benchmark in HL Treatment…

… Introduction to ADCs in Cancer Therapy The advent of targeted therapies has revolutionized the field of oncology, offering new hope and improved outcomes for patients with hematological malignancies. Among these innovative treatments, Antibody-Drug Conjugates (ADCs) such as Inotuzumab Ozogamicin (INO) and Gemtuzumab Ozogamicin (GO) have emerged as significant advancements. These therapies uniquely combine the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic agents, specifically targeting cancer cells while sparing healthy tissue. However, the clinical application of INO and GO has unveiled a challenging aspect of their use: liver toxicity, including sinusoidal obstruction syndrome (SOS) and thrombocytopenia. Drawing…

… In the rapidly evolving field of oncology, colorectal cancer (CRC) represents a significant area of research and clinical development. Innovations in genetic profiling and targeted therapies have led to considerable advancements in the treatment of CRC, offering new hope and improved outcomes for patients. This article, grounded in the comprehensive data presented by Heinz-Josef Lenz, MD, from the USC Center for Cancer Drug Development at the 2024 MOASC Annual Oncology Summit & Research Symposium in Newport Beach California, aims to provide oncologists with an in-depth overview of the current state and future directions in CRC treatment. [EXCLUSIVE VIDEO with…

… [VIDEO & SLIDES] Alex Chehrazi –Raffle, MD, City of Hope – 2024 MOASC Annual Oncology Summit & Research Symposium In the ever-evolving field of oncology, the management of non-metastatic prostate cancer represents a significant area of interest due to the potential for curative treatment outcomes. With advancements in diagnostic techniques and treatment modalities, the approach to treating non-metastatic prostate cancer is becoming increasingly sophisticated. This article builds upon the insights provided by Alex Chehrazi-Raffle, MD, from the City of Hope Comprehensive Cancer Center, to explore the nuanced strategies in the systemic treatment of non-metastatic prostate cancer. It covers the…

… [VIDEO with 39 SLIDES] – Dr. Rebecca Shatsky, MD from the 2024 MOASC Annual Oncology Summit & Research Symposium In the rapidly advancing field of breast cancer treatment, the emphasis on personalizing therapy to individual patient needs and tumor characteristics has become increasingly paramount. Dr. Rebecca Shatsky, MD an esteemed Associate Professor of Clinical Medicine at UC San Diego, provides an in-depth exploration of the latest strategies and breakthroughs in breast cancer management at the 2024 MOASC Annual Oncology Summit & Research Symposium. This article delves into the critical aspects of her presentation, which spans the gamut from the…

Overview The U.S. Food and Drug Administration (FDA) has granted approval for the use of inotuzumab ozogamicin (Besponsa, Pfizer) in pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). This decision represents a significant advancement in the treatment options available for this particular patient population. [Exclusive Video] Efficacy and Safety of Inotuzumab Ozogamicin (BESPONSA) – Mojtaba Akhtari, MD, FACP-Professor of Medicine-Loma Linda University – MOASC 2024 Advances in Oncology … Efficacy Evaluation The approval was based on data from a multicenter, single-arm, open-label study involving 53 pediatric patients aged 1 year…

On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene USA, Inc., for the treatment of relapsed or refractory follicular lymphoma (FL) following two or more lines of systemic therapy. Study Background: ROSEWOOD Trial (BGB-3111-212) The approval was based on findings from Study BGB-3111-212, also known as the ROSEWOOD trial (NCT03332017). This open-label, multicenter, randomized trial enrolled 217 adult patients with relapsed or refractory FL after at least two prior systemic treatments. Patients were randomized in a 2:1 ratio to receive either zanubrutinib 160 mg orally twice daily in combination…

The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific antibody is being evaluated for its efficacy in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy. The Importance of Priority Review Priority Review is granted by the FDA to investigational therapies that have the potential to significantly improve the safety or effectiveness of treating serious conditions compared to standard applications. This designation shortens the review period to six months, as opposed to the standard 10 months. If approved, epcoritamab-bysp (EPKINLY®)…

Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set of challenges for both patients and healthcare providers. Angela Fleischman, MD at Spotlight on Myelofibrosis 2024 from MOASC, focuses on the critical role of Janus kinase (JAK) inhibitors in managing this disease. Despite the common association of JAK2 V617F mutations with myeloproliferative disorders, Fleischman underscores the effectiveness of JAK inhibitors across various genetic mutations, expanding the therapeutic horizon beyond JAK-mutated patients alone. [VIDEO] 2024 Myeloproliferative Neoplasms Updates [33 SLIDES] – Angela Fleischman, MD, PhD – Spotlight on Hematology 2024 MOASC … Clinical Challenges of Myelofibrosis…

Zahra Pakbaz, MD, shed light on a range of critical findings from the American Society of Hematology (ASH) meeting, with a particular focus on the dynamic sphere of benign hematology. Amidst a potential shortfall in expertise within this field, Pakbaz’s research, conducted with a team of dedicated students, highlighted the pivotal role that hematologists play in the management of non-cancer blood disorders, such as sickle cell disease. This article delves into the significance of Non-Malignant Hematology Clinics, presenting Pakbaz’s insights on the vital presence of these clinics and the exciting potential that gene therapy holds for sickle cell disease and…

In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various forms of lymphoma. Dr. Stefan Ciurea’s comprehensive discussion at a recent medical conference highlighted the significant strides made in this innovative treatment modality, underscoring its potential and challenges. This article delves into the updates, studies, and clinical experiences shared by Dr. Ciurea, offering a detailed view for physicians engaged in the field. [69 SLIDES with VIDEO] 2024 CAR-T-cell Hematology Updates – Stefan Ciurea, MD – MOASC … Advancements in CAR T-cell Therapy for Multiple Myeloma Recent trials have showcased the…

ASH Groundbreaking Trials and Therapies Transform Multiple Myeloma Treatment The recent American Society of Hematology (ASH) meeting showcased significant advancements in multiple myeloma treatment, with a particular focus on integrating CD38 monoclonal antibodies into frontline therapy and exploring the benefits of quadruplet regimens. These developments promise to reshape patient care, offering new hope for those battling this challenging disease and were highlighted at the MOASC Spotlight on Myeloma 2024. [VIDEO with 36 SLIDES] 2024 Multiple Myeloma Updates – Lisa X. Lee, MD … The Griffin and PERSIUS Trials: A New Era in Myeloma Treatment Dr. Lisa X. Lee highlighted the…

Assessing the Impact of COVID-19 on Cancer Screening and Diagnosis Rates in the United States: A 2020 Overview The COVID-19 pandemic, emerging from the discovery of the SARS-CoV-2 virus in 2019, has led to widespread disruptions across various sectors, including healthcare. Undiagnosed Cancer & COVID-19 is one of the less visible but highly impactful disruptions has been in the field of cancer screening and diagnosis. The pandemic’s interference with routine health care and cancer screening services has led to a significant drop in cancer diagnoses across the United States. This article delves into a comprehensive analysis conducted to understand the…

March 1, 2024 – In a significant advancement for lung cancer treatment, the Food and Drug Administration (FDA) has approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed. This new therapy is designated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as confirmed by an FDA-approved diagnostic test. Traditional Approval Granted for Amivantamab-vmjw The FDA has also issued traditional approval for amivantamab-vmjw for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. This approval…

A New Horizon in Gene Editing In the rapidly evolving field of genetic medicine, a groundbreaking development has emerged with the introduction of a novel CRISPR-based tool, MEGA-CRISPR. This innovation promises to bring a significant transformation to cancer therapy, setting a new standard for precision medicine. Traditional CRISPR systems, known for their ability to edit DNA, have been pivotal in advancing genetic research and therapy. However, MEGA-CRISPR diverges from this path by targeting RNA instead, offering a more flexible and reversible method for modifying cellular behavior. This shift not only enhances the potential of cancer-fighting cells but also paves the…

The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with the introduction of rusfertide, a groundbreaking drug developed through the collaborative efforts of the Icahn School of Medicine at Mount Sinai. This innovative therapy has shown promising early success in clinical trials, heralding a potential paradigm shift in the management of PV, a condition that has historically been challenging to treat effectively. “Rusfertide appears to represent a significant step forward in treating polycythemia vera through its unique approach of limiting the amount of iron available for blood cell production,” states…

On February 15, 2024, the Food and Drug Administration (FDA) approved tepotinib, commercially known as Tepmetko®, for its use in adult patients with metastatic non-small cell lung (NSCLC) cancer exhibiting MET exon 14 skipping alterations. This milestone followed its previously granted accelerated approval, reflecting a substantial leap forward in precision medicine for lung cancer. Tepotinib’s Path from Accelerated to Traditional Approval Originally granted accelerated approval based on promising outcomes from the VISION trial, tepotinib’s journey to full FDA endorsement was underpinned by clinical scrutiny and an expanded dataset, affirming its role in targeting MET-dependent tumor cells in NSCLC. The European…

Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews Below) On February 20th, 2024 the Teclistamab FDA approval of TECVAYLI® (teclistamab-cqyv) for biweekly dosing was announced as a significant advancement in the treatment landscape for relapsed or refractory multiple myeloma (RRMM), offering a new beacon of hope for patients battling this incurable blood cancer. This approval underscores the commitment to addressing the complex needs of patients with multiple myeloma, especially those who have shown resistance to previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Understanding Multiple…

What is the new treatment for metastatic melanoma? On February 16, 2024, the medical community witnessed a significant milestone in the fight against metastatic melanoma, a notoriously aggressive form of skin cancer responsible for a substantial number of cancer-related deaths worldwide. The Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), marking the advent of the first cell therapy for adult patients with unresectable or metastatic melanoma that have exhibited resistance to conventional treatments. This novel T cell immunotherapy, developed by Iovance Biotherapeutics, Inc., is tailored for patients who have previously undergone treatment with a PD-1 blocking antibody…

On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name Tagrisso by AstraZeneca Pharmaceuticals LP, in combination with platinum-based chemotherapy. This approval offers a new treatment avenue for adult patients battling locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by specific genetic mutations: EGFR exon 19 deletions or exon 21 L858R mutations. These mutations must be identified using an FDA-approved test, ensuring the targeted application of this therapy. The Clinical Landscape of NSCLC (Non small cell lung cancer) Non-small cell lung cancer represents a significant portion of lung…

We asked 5 top KOLS at ASCO GI 2024 the same questions on MRD and CTDNA testing. You might be surprised by the diverse answers. Investigating MRD and ctDNA Testing: Insights from Top KOLs at ASCO GI 2024 Introduction The landscape of oncology research is continually shaped by advancements in minimal residual disease (MRD) and ctDNAtesting (circulating tumor DNA), particularly in colorectal cancer. The American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) serves as a pivotal platform for sharing groundbreaking research and clinical insights among oncologists and researchers. We asked five top Key Opinion Leaders (KOLs) at ASCO GI…

… Anup Kasi, MD, Associate Professor and Vice Chair of GI Oncology at the University of Kansas Medical Center, is propelling forward the battle against metastatic pancreatic cancer, shedding light on the transformative potential of targeted therapies. Among these, KRAS G12C inhibitors and protein degraders have emerged as crucial weapons in targeting the KRAS gene mutations, which are pivotal in the oncogenesis of not only pancreatic cancer but also colorectal and lung cancers. This marks a significant shift towards precision medicine, focusing on the molecular underpinnings of cancer.KRAS Gene’s Role in OncologyThe KRAS gene, a member of the mammalian Ras…

Suneel Kamath, MD: [00:00:00] So this this trial that the tech 24 trial was really looking at a pan G. I. Population evaluating tucatinib plus trastuzumab and then full fax chemotherapy across a number of different G. I. Cancer. The thing that was really the strength of it is that this is recognizing really that her to amplification is extremely important biomarker. wE first found it in breast cancer, of course, and have been using gastric cancer and esophageal cancer for many years, but we’re starting to recognize more and more that this does really have kind of a tumor…

Van K. Morris, MD: [00:00:00] Thanks Allen for for having me and letting me represent our team of investigators who reported the results from the NRG-GI005 (COBRA) trial. This past weekend at the ASCO GI Symposium in San Francisco, this is a phase two trial that evaluated the role of circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with low risk stage two eight colon cancer. This was also the first trial that the NCI ever supported evaluating circulating tumor DNA as an integral biomarker for any solid tumor type. So we all recognize that in…

Naureen Starling, MD: [00:00:00] Of course. So AZUR-2, as you said, is a global study. Open label, randomized, running in over 245 centers in over 26 countries globally. So a global study and patients. So 711 participants will be recruited with DMMR or MSI high. Resectable colon cancer stay with a clinical stage of T four N zero or stage three. And that’s by clinical staging. And participants will be randomized on a two to one basis between the experimental arm versus the control arm. And in the experimental arm, participants randomized to that arm will have neoadjuvant doss, which…

Sakti Chakrabarti, MD: [00:00:00] So Dream GI is a national database through which we collect data on localized GI cancer patients who have MSI high tumors and who have received immunotherapy up front. We also call it new adjuvant immunotherapy. The idea behind this database is that new adjuvant immunotherapy is being given to patients who have localized GI cancers and MSI high tumor, right now, outside of a clinical trial, because many of these patients are not good surgical candidates. If those patients are getting the treatment, it makes a lot of sense to collect that data and analyze…

Michael Weickert, PhD: [00:00:00] So the first thing I want to explain is Zelenirstat is a first in class therapy targeting a new target that’s never been drugged before for any indication. So this is the first time it’s been studied in patients and we do what’s called a phase one study which is primarily to identify safety. Is it safe to dose this new drug which has never been dosed before at a new target that’s never been drugged before? So our study was designed to escalate the dose gradually in a series of patients that are not selected…

Thejus Jayakrishnan, MD: [00:00:00] Those of you who have listened to the keynote address today by Dr. Ng from Dana Farber, she highlighted how there is an increasing incidence of early onset GI cancers. In fact, we’re seeing more and more young patients Young people developing cancers and the largest increase is happening in GI cancers and specifically in cholangiocarcinoma. So over the years we’ve seen more and more patients dying from cholangiocarcinoma and we do not know what is the reason for this and we also don’t know are there any features that are unique to young patients compared…

Sawyer Bawek, MD: So in colorectal cancer with liver metastasis, studies have shown that immunotherapy has a poor response on those patient populations. So what we wanted to do is one look at the role of immunotherapy and gastroesophageal cancer in patients with liver metastasis and see if it also has a poor response. So we looked at all phase three. randomized controlled trials looking at immunotherapy um, in advanced metastatic gastroesophageal cancer. And after analyzing all the studies, we found about seven studies that had data on overall survival and progress and free, progression free survival with liver metastasis.…

Anup Kasi, MD: [00:00:00] So this is an investigative initiated trial called the EPIC trial. Where we’re investigating n fotamibidotin, which is an antibody drug conjugate as a single arm, non randomized. Phase two study a single institution study at our site at University of Kansas in patients with advanced pancreatic cancer in the second line and beyond setting. As a phase two study, this primary objective of this study is looking at the objective response rate. And then we do have some secondary objectives such as OS, PFS, and safety analysis as well. OncologyTube: Given the aberrant overexpression of…

Simron Singh, MD: [00:00:00] So radioligand therapy is like in a new emerging treatment for cancer. where we try to inject radioactive isotopes through the body that bind to the cancer receptors and are taken up by the cancer cells and then the cancer cells are killed, but generally preserve healthy tissue. So the NETTER-2 clinical trial is the first clinical trial to date that examines this type of therapy as the first line therapy in any cancer. And so specifically with the NETTER-2 trial, we looked at advanced Grade two and grade three neuroendocrine cancers from the G. I. Tracked…

Howard S. Hochster, MD: [00:00:00] Um, first of all, this is for late line colorectal cancer after the standard chemotherapy and targeted therapy drugs. it’s a space where we’re seeing new drugs approved for colon cancer, but many people continue to have the need for additional treatments once they finish the approved drugs. this particular drug is quite novel, ME344. we are working, in the, AGIC group, the Academic GI Cancer Consortiwhich is an academically based Phase II national consortium. with MEI Pharma to test this drug. It’s novel because it interrupts mitochondr m my this is novel because it,…

OncologyTube: [00:00:00] Okay. We’re here at ASCO GI 2024. And, we have the honor of, having Dr. Christopher Lieu, MD medical doctor, associate director for clinical research, co director gastrointestinal medical oncology at University of Colorado and Aurora, Colorado. Dr. Lu, thank you so much for joining us. Well, thank you for having me. Okay, today we’ll be discussing the NRG-GI008 colon adjuvant chemotherapy based on evaluation of a residual disease otherwise known as the circulate North America trial, which is featured here at ASCO GI 2024. So Dr. Liu, can you provide an overview of the NRG G. I. …

OncologyTube: [00:00:00] Okay, here we are at ASCO GI 2024. We have Dominik Paul Modest, MD medical doctor from Charite,University of Medicine in Berlin. Dr. Modest, thank you so much for joining us today. You’re welcome. Today, we’ll be discussing health related quality of life in patients with metastatic colorectal cancer treated with sotorasib and panitumumab versus Trifluoridine, Tirapercel and regorafenib in Codebreak300, which is featured here at ASCO GI 2024. Dr. Matas, can you provide an overview of the Codebreak300 trial? Dominik Paul Modest, MD: Sure. Um, it’s a spectacular trial in a way because it’s three arm in…

OncologyTube: [00:00:00] Okay. Okay, we’re here at ASCO GI 2024 and we have Dr. Anthony B. El-Khoueiry, MD a medical doctor, associate professor of medicine at USC Norris Comprehensive Cancer Center, USC, in Los Angeles. Dr. El Khoury, thank you so much for joining us today. Pleasure. Okay. Today we’ll be discussing Tizolizumab plus chemotherapy with or without Bevacizumab and advanced biliary tract cancer results from a randomized proof of concept phase two trial, otherwise known as the IMBRAVE151, which has been featured here at ASCO GI 2024. So Dr. Okahiri, can you provide an overview of the IMBRAVE151 study…

OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Dr. Riccardo Lencioni, MD medical doctor, professor of radiology and director of cancer imaging program at the Pisa University School of Medicine in Italy. Dr. Lencioni, thank you so much for joining us. My pleasure. Today we’ll be discussing the Emerald 1, a phase 3 randomized placebo controlled study of tastes combined with Dorvalumab with or without Bevacizumab in patients with unresectable hepatocellular cancer. carcinoma eligible for embolization, which is featured here at ASCO GI 2024. Dr. Lencioni, can you provide the overview for the Emerald One…

OncologyTube: [00:00:00] We have Dr. Milind Javle, MD. He is from the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Thank you for joining Milind Javle, MD: us today. So I’m very excited to be here and discuss a phase 3 trial that has just been initiated in FGFR altered cholangiocarcinoma. To give you a background, FGFR altered cholangiocarcinoma can be treated now with Pemigatneb. Uh, and furibatinib. These are, uh, agents that are FDA approved. Unfortunately, resistance inevitably occurs, and this occurs after six to eight months, and after that,…

OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Jeanne Tie, MD a medical doctor, the medical oncology lead for the lower GI tumor stream at Peter MacCallum Cancer Center and senior research fellow within the Division of Personalized Oncology at the Walter and Eliza Hall Institute in Australia. Dr. Tie, thank you so much for joining us today. Jeanne Tie, MD: You’re welcome. Pleasure to OncologyTube: be here. Today we’ll be discussing circulating tumor DNA analysis informing adjuvant chemotherapy and locally advanced rectal cancer. The randomized AGI TG dynamic rectal study, which is being highlighted here…

OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Ghassan K. Abou-Alfa, MD, medical doctor from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York. Dr. Abu Alfa, thank you so much for joining us today. Ghassan K. Abou-Alfa, MD: Thanks so much, Alan. Nice to be OncologyTube: here. Today, we’ll be discussing PROOF 301, results of an early discontinued randomized phase three trial. Dr. Abu Alfa, could you please provide an overview of the PROOF 301 Ghassan K. Abou-Alfa, MD: study? Well, thanks so much, Alan, and, uh, by all means,…

OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Ethan Ludmir, medical doctor and the assistant professor, Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Ludmir, thank you for joining us Ethan Ludmir, MD: today. Thank you for having me. OncologyTube: Today we’ll be discussing addition of metastasis directed therapy to standard of care systematic therapy of oligometastatic pancreatic ductal adenocarcinoma. Results of a multicenter randomized phase 2 trial, which is being featured here at ASCO GI 2024. So, Dr. Ledmeyer, can you…

OncologyTube: Okay, we’re here at ASCO GI 2024. We have Dr. Manish Shah, medical doctor, and the director of gastrointestinal oncology program at Weill Cornell Medicine in New York. Thank you so much Manish Shah, MD: for joining us today. It’s great to be here. Thank you. OncologyTube: Today, we’ll be discussing first line pembrolizumab plus chemotherapy for advanced esophageal cancer five year outcomes from the Keynote 590 study, a phase three study featured here at ASCO GI 2024. So Dr. Shaw, could you provide an overview of the five year follow up data from the Keynote Manish Shah, MD:…

  OncologyTube: Okay, we’re here at ASCO GI 2024. We have Dr Stacy Cohen, medical doctor and an associate professor of clinical research division at Fred Hutch Cancer Center and University of Washington in Seattle. Dr Cohen, thank you so much for joining us today. Thank you for having me. All right, today we’ll be discussing prognostic value of circulating tumor DNA testing in patients with rectal cancer after neoadjuvant therapy and surgery. Um, a, uh, presentation released here at ASCO GI 2024. So, Dr. Cohen, could you provide a summary of the research on the prognostic implications of, uh,…

Transcript:   Okay, we’re here at ASCO G. I. 2024 and we have Dr. Vivek Sivaya, Medical Doctor, Chief Early Phase Drug Development at the Sarah Cannon Research Institute, Nashville, Tennessee. Dr. Sivaya, thank you so much for joining us today. Thank you so much. Okay, today we’ll be discussing durable efficacy of sulprocatinib in patients with RAT Fusion Plus solid tumors with a focus on GI tumors, the Libretto 001, a study featured here at ASCO GI 2024.So, Dr. Sabaya, could you provide an overview of the Libretto 001 study? The LIBERATO 001 study is a Phase I II…

The full Video OnDemand is now available! This live, virtual, interactive patient education event includes presentations and panel discussions covering general subjects relevant to a diverse range of blood cancers and treatment options. Top medical professionals present patient-focused discussions to help educate the patient and caregiver communities to become advocates for their own health and well-being. Topics include treatment options, side effects, complications, second and third-line treatments, and clinical trials. This event offered an opportunity for a question and answer session with experts about the new information and rapid developments continually emerging in blood cancer treatment options. This version is…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss a RET patient’s risk of recurrence after a lobectomy and chemo. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss immunotherapy treatments for BRAF+ non-smoking patients. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss what first-line treatment options should be for a patient with stage IV disease and no brain mets. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss when patients should consider biomarker retesting, and briefly compare pralsetinib and selpercatinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss current trends toward neoadjuvant TKI treatment options. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss pemetrexed and bevacizumab use in squamous cell lung cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss treatment options for a patient who has developed new brain lesions while on alectinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using alectinib for a DCTN1 ALK fusion. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using cabozantinib, and its potential side effects. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using off-label treatments. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses identifying and treating NRG1 fusions in NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss RNA testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

By. Naval Daver, MD Date: January 12, 2024 Introducing Naval Daver, a faculty member specializing in MD Anderson Cancers in Houston, Texas. As one of the co-chairpersons at a significant conference, Naval values the enriching experience it has offered. During Naval’s presentation, the focus centered on innovative nano-crack-based combination approaches. Specifically, the exploration of novel combinations involving aneroclax with three distinct antibodies—id age in habits, three d one twenty-three antibodies, and three forty-seven antibodies—revealed promising outcomes. These combinations showcased improvements in response rates and survival, indicating optimized durations and dosing for aneroclax and targeted therapy. REGISTER NOW TO JOIN US AT THESE…

By: Parrish Phimes, Date: January 12, 2024 Parrish Phimes, a professor of Intology at the University of Oxford and affiliated with the Oxford University NHS Trust, recently presented insights during an academic gathering. In the conference, Dr. Phimes explored the molecular changes occurring in air cells leading to leukemia, elucidating the underlying mechanisms. Among the aspects of his presentation was an approach to identifying patients likely to respond well or poorly to treatment, specifically chemotherapy and transplantation. Dr. Phimes emphasized the use of genetic changes to categorize patients, distinguishing those expected to have favorable outcomes from those facing challenges in their…

By: Pramilla Krishnamurthy, MD Date: January 12, 2024 Pramilla Krishnamurthy, md, a consultant hematologist at King’s College Hospital in London, engaged in a comprehensive discussion during a recent conference. The focus of her discourse was to scrutinize potential inequities in outcomes for patients diagnosed with AML (Acute Myeloid Leukemia). Dr. Krishnamurthy delved into the intricate interplay of factors contributing to these differential outcomes, highlighting disease biology as a primary determinant. She emphasized the multifaceted nature of the issue, considering variables such as age, with particular attention to teenagers and young adults who might face comparatively worse outcomes. Dr. Krishnamurthy also explored…

By: Priyanka Meta Date: January 11, 2024 Priyanka Meta, a meteorology consultant associated with the University Hospitals of Bristol and Western Managers in the UK, recently presented at a conference on the rare disease BPDCN, also known as plastic plasma cytodendritic cell leukemia neoplasm. Specializing in myeloid diseases, Priyanka discussed historical treatments, challenges, and recent developments in managing BPDCN. During her presentation, she highlighted treatment advances, including Debla Holmes and Degrasse therapies, considered significant in managing the disease. Priyanka also discussed recent developments aimed at improving outcomes for patients with this ailment. REGISTER NOW TO JOIN US AT THESE UPCOMING…

Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the integration of circulating tumor DNA (ctDNA) and Minimal Residual Disease (MRD) assessment as essential elements in shaping medical therapy decisions. In Dr. Mchayleh’s perspective, leveraging ctDNA and MRD can serve as a determinant in adjusting the intensity of treatment protocols.During his address at MDAS, Dr. Mchayleh highlights the potential of ctDNA as a tool for MRD monitoring and early recurrence detection. Expressing concern that this approach is currently underused, he stresses the importance of incorporating ctDNA and MRD analyses at the early stages of treatment.…

In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual Disease (MRD). Dr. Mchayleh discusses the application of MRD in colorectal and breast cancer, highlighting its ability to predict early recurrence before radiologic signs appear, as evidenced in various trials. He emphasizes the sensitivity of MRD testing in detecting early recurrence.Dr. Mchayleh advocates for a proactive approach to using MRD in the neoadjuvant setting for early breast cancer. He envisions a shift where MRD not only predicts treatment responses but also influences therapeutic strategies based on MRD outcomes, particularly gauging the clearance of plasma during…

David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s Research Executive Committee, is scheduled to participate in an upcoming interview. During this discussion, he will provide insights into his recent study, titled “Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL / SLL in the US Community Setting.”In the interview, Dr. Andorsky will offer an overview of the study, highlighting changes in the treatment landscape of BTK inhibitors for CLL / SLL. Specifically, he will discuss variations in the use…

Dipti Patel-Donnelly, a medical oncologist at the Virginia Cancer Specialists, leads a study titled “How Can We Manage High-Risk Hematologic Malignancies in the Community?” The study investigates the impact of integrating novel agents, BiTe therapy, CAR-T, and transplantation into the standard of care for hematologic malignancies in community settings.Dr. Patel-Donnelly shares insights based on her experience, discussing the challenges and opportunities associated with implementing advanced therapies in local cancer care. The educational session emphasizes the need to address access issues for patients with hematologic malignancies in the community, focusing on specific diagnostic, supportive, and treatment challenges in acute leukemia, high-grade…

In the realm of advancements in CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL), Dr. Brian Hill, MD, PhD, stands at the forefront to discuss the findings of the ZUMA-2 and ZUMA-18 studies. The ZUMA-2 study reported a median overall survival (OS) of 46.4 months with brexu-cel, showcasing its efficacy in patients with relapsed/refractory MCL and a complete response (CR). Dr. Hill will explore the implications of these findings, contributing to the evolving landscape of CAR T-cell therapy for MCL. Moreover, he will discuss considerations surrounding the durability of response observed in these patients, adding a dimension to the…

Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study titled Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy. The research indicates comparable response rates in Daratumumab-naïve (DN) and Daratumumab-refractory (DR) patients, with a notable difference in median overall survival (OS). The study explores potential reasons for the higher OS in the DN group and discusses the impact of these findings on treatment decisions for highly refractory multiple myeloma patients. The research also notes similar treatment-related toxicities between DN and DR groups but observes a higher rate of rehospitalization…

John F. Seymour, MBBS, Ph.D., FRACP, a clinical haematologist and the Director of the Haematology Department at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, VIC, Australia, conducted a groundbreaking Phase 1 study on BGB-16673, a pioneering Bruton tyrosine kinase (BTK) degrader. The focus of this study was on patients grappling with relapsed or refractory B-cell malignancies, particularly those who had faced disease progression despite undergoing treatment with BTK inhibitors. The study aimed to delve into the unique mechanism of action of BGB-16673, specifically highlighting the chimeric degradation activating compound (CDAC) structure responsible for BTK degradation. Understanding this…

Asya Nina Varshavsky-Yanovsky, MD, PhD, serves as an Assistant Professor within the Department of Bone Marrow Transplant and Cellular Therapies. The study, “Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies,” led by Dr. Varshavsky-Yanovsky, delves into the efficacy and safety of elranatamab in Black or African American patients grappling with relapsed/refractory multiple myeloma (RRMM). This investigation explores critical metrics such as the overall response rate (ORR) and median duration of response (DOR). Notably, elranatamab exhibited a promising ORR of 58.3% and a median DOR of 18.4 months among…

In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology, investigates a combination therapy for treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL) patients. The study focuses on the safety and efficacy of combining Sonrotoclax, a second-generation BCL2 inhibitor, with Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor. Preliminary results suggest outcomes, with a focus on responses, tolerability, and safety.The combination of Sonrotoclax and Zanubrutinib presents an advancement in the treatment landscape for TN-CLL/SLL patients. Compared to existing treatments, this combination demonstrates potential advantages, including a safety profile with manageable treatment-emergent adverse events. Dr. Tam explores aspects…

Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology at SA Pathology in Adelaide, Australia. In collaboration with his colleague, Chris Hahn, MD, who heads the Molecular Pathology Research Laboratory, Dr. Scott shares insights into a groundbreaking study during an interview. The research stemmed from a case involving a family with thrombocytopenia and neutropenia, where the mother developed acute myeloid leukemia and myelodysplastic syndrome.Their investigation led to the discovery of a novel predisposition gene, ERG, associated with bone marrow failure and hematological malignancies. The study uncovered a missense mutation in the ERG gene among…

Rabi Hanna, MD, from the Department of Pediatric Hematology Oncology and BMT at Cleveland Clinic Children’s, conducted a study on AsCas12a gene editing with EDIT-301 for severe Sickle Cell Disease (SCD) and transfusion-dependent β-thalassemia (TDT). The research aimed to evaluate the efficacy of this approach in achieving normalization of hemoglobin levels and increased production of fetal hemoglobin (HbF) in affected patients.The results of EDIT-301 in patients with severe SCD and TDT contribute to the growing field of gene-edited therapies for hemoglobinopathies. This novel approach, targeting HBG1/2 promoters, has potential for outcomes in patients with these conditions, advancing our understanding of…

Evandro Bezerra, MD, hematologist and assistant professor at The Ohio State University Wexner Medical Center, leads research focused on improving the outcomes of patients with hematologic malignancies. The study, Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry, delves into the real-world outcomes of brexucabtagene autoleucel, known as brexu-cel, for adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-cell ALL).Intriguingly, the study reveals that a substantial 91% of the patients included would have been ineligible for the ZUMA-3 trial. This raises important questions about…

In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the focus is on investigating the efficacy of Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting.The study delves into the real-world treatment patterns and outcomes of patients grappling with relapsed/refractory DLBCL who have undergone tafasitamab treatment within community oncology settings. A key objective is to draw comparisons between these findings and the results observed in the L-MIND clinical trial.Dr. Feinberg’s research particularly emphasizes a racially and ethnically diverse patient population, with a notable representation from typically underrepresented…

At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina, discussed a multicenter study focusing on the toxicity and efficacy outcomes associated with Teclistamab in patients above the age of 70 with relapsed refractory multiple myeloma.The retrospective analysis included nearly 100 patients, with around one-third of them aged 70 or above. Dr. Hashmi highlighted the challenges faced by older patients, such as compromised physical performance status, organ dysfunction, renal issues, and other high-risk disease features. Over a median follow-up of approximately three and a half months, the study revealed comparable safety and efficacy outcomes between…

Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study titled “Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412).”This Phase II study investigated the efficacy and safety of combining immune checkpoint blockade with the CD30-targeting antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Classic Hodgkin lymphoma (cHL).The study’s importance lies in its approach to addressing the challenges of cHL treatment. By combining immune checkpoint inhibitors (Ipilimumab and Nivolumab) with brentuximab vedotin,…

In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a study on predicting progression-free survival (PFS) in early-stage Hodgkin lymphoma (E-HL). Dr. Evens, a seasoned researcher and clinician, will provide insight into the E-HIPI model, which identifies factors such as nodal location, sex, and key continuous variables as essential in prognosticating PFS.When asked for a brief overview of the study, Dr. Evens will share insights into the research’s significance and potential implications for oncology. Regarding the E-HIPI model, he will elaborate on how factors like nodal location, sex, and key continuous variables contribute to predicting…

In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics in pediatric ALL patients. The research aims to predict long-term responses to anti-CD19 CAR T cells by analyzing gene expression profiles. Dr. Melenhorst reveals a cytogram profile linked to B cell replacement, a key remission biomarker. The interview explores correlations in CAR T cells’ functionality, emphasizing the potential for manipulation to enhance efficacy. Insights from a mouse model underscore the importance of the type 2 pathway in sustaining remission, offering perspectives for CAR T therapy development.

Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone. The discussion covered the clinical significance of achieving minimal residual disease (MRD) negativity, with Zandra correlating the depth of response to long-term outcomes. She expressed cautious optimism for the high-risk patient population, highlighting the need for extended follow-up. Safety and tolerability considerations were addressed, with Zandra acknowledging numerical imbalances in deaths and emphasizing the importance of awaiting further survival results. ASH 2023 witnessed an…

At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at the Sylvester Comprehensive Cancer Center, University of Miami, engaged in a discussion about the final analysis of the Sinterra study. The study, a randomized phase two trial, aimed to assess the efficacy and safety of daratumumab monotherapy in patients with intermediate or high-risk smoldering multiple myeloma.Dr. Landgren outlined the international multicenter nature of the trial and its objective to investigate whether daratumumab could delay or prevent the progression from smoldering myeloma to multiple myeloma.

Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi, a medical doctor and lymphoma specialist at Memorial Sloan Kettering in New York, engaged in a conversation.Navigating the pronunciation of a treatment, Dr. Falchi provided an overview of Mosunetuzumab’s role as a first-line therapy for high tumor burden follicular lymphoma, based on the initial results from a multicenter phase 2 study.Dr. Falchi unfolded the narrative behind the study, emphasizing its roots in addressing the limitations of traditional chemotherapy. He highlighted the study’s optimism, revealing Mosunetuzumab’s high deliverability and patient tolerance. The efficacy results were promising,…

At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown Lombardi Comprehensive Cancer Center at MedStar Health, provided details about a study focused on the time to achieve platelet count response after intravenous Fc-gamma receptor antagonist (Efgartigimod) in adults with primary immune thrombocytopenia.This phase three multicenter double-blind placebo-controlled randomized clinical trial involved multiple countries and targeted adult patients aged 18 or older diagnosed with ITP for a minimum of three months. Dr. Broome explained that these patients had failed at least one therapeutic intervention and were either not responding to their second intervention or had…

By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical doctor and professor of medicine at Stanford University School of Medicine, shared captivating insights into the transformative landscape of lymphoma treatment during an interview. The discussion centered around the pivotal TRANSFORM study, introducing Lysocabtagene maraleugel as a second-line therapy for large B cell lymphomas resistant to frontline treatments. Dr. Alizadeh eloquently elaborated on the trial’s resounding success, emphasizing its profound shift towards personalized therapies and the abandonment of traditional methods like high-dose chemotherapy and transplantation. The interview seamlessly transitioned into a sub-study, exploring the role…

By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical doctor and associate professor of hematology from the University of Florence Medical School in Italy, engaged the audience in a discussion about the Phase 3 Medalist study.Dr. Santini commenced her presentation by providing a comprehensive overview of the Medalist trial initiated in 2016. This clinical investigation focused on assessing the response to Luspatercept, an active erythroid maturation agent. The study specifically targeted lower-risk myelodysplastic syndromes (MDS) patients with transfusion dependence who were refractory or ineligible for conventional erythropoietic stimulating agents.The trial involved the administration of…

By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI in Rocky Mountain Cancer Centers, part of the U.S. Oncology Network, for a discussion about a phase two study on the outpatient administration of Teclistamab, a bispecific antibody targeting BCMA in patients with multiple myeloma. Dr. Rifkin explains that the study aims to bring new classes of myeloma drugs into the clinic and community more practically. Teclistamab, being the first bispecific antibody released for multiple myeloma, initially mandated hospitalization due to concerns about cytokine release syndrome (CRS) and neurologic dysfunction. The study seeks to introduce…

By. Halle Moore, MD Date. 12/13/2023 Halle Moore, MD, the Medical Doctor and Director of Breast Medical Oncology and Co-Director for the Comprehensive Breast Cancer Program at Cleveland Clinic, shares insights into a study focusing on fertility preservation and assisted reproductive technologies in breast cancer patients who interrupt endocrine therapy to attempt pregnancy.Dr. Moore discusses the eligibility criteria for women in the study, emphasizing factors such as age, stage of breast cancer, and duration of adjuvant endocrine therapy. The study, aimed at assessing the short-term safety of interrupting endocrine therapy for pregnancy, explores outcomes related to assisted reproductive technology and…

By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of triple-negative breast cancer (TNBC), will provide answers to questions during the interview. The discussion will cover the significance of evaluating immune landscapes in TNBC, the use of technologies such as NanoString IO360 and Digital Spatial Profiling, the association between immune-related proteins and different landscapes, the exploration of the PI3K-Akt signaling pathway, and the implications of single-cell sequencing findings on targeted therapies. Dr. Chumsri’s insights aim to offer objective perspectives on understanding TNBC and guiding potential treatment strategies.

Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a medical oncologist from the University of North Carolina Chapel Hill. Graciously taking the time to engage in conversation, Allen extended his gratitude to Dr. Abdou for joining the discussion.In their exchange, the focus shifted to the intricate realm of medical practice, specifically exploring the practice patterns associated with the sequential use of antibody drug conjugates after antibody drugs. Dr. Yara Abdou delved into the complexities of this topic, shedding light on the challenges faced by providers in sequencing these drugs due to the yet-to-be-fully-understood efficacy…

By: Ibrahim Aldoss, MD – City of HopeDate: 12/11/2023Revumenib Monotherapy in KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at McMaster University, shedding light on the groundbreaking findings from the phase three basis trial concerning the anti-tissue factor pathway inhibitor, Marstacimab. The conversation delves into the study’s design and outcomes, focusing on a cohort of patients with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors.Dr. Matino provides a comprehensive overview of the study, detailing the observational phase, loading doses, and subsequent treatment phases involving Marstacimab. The emphasis is on the subcutaneous administration of the drug, representing a pivotal advancement in the…